UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For the quarterly period ended
OR
Commission File Number:
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
| (Address of principal executive offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer ☐ | Accelerated filer ☐ | |
| Smaller reporting company | ||
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As of November 16, 2026,
CHANGE AGENTS CORPORATION
FORM 10-Q
For the Quarterly Period Ended September 30, 2026
Table of Contents
i
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements.
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, | December 31, | |||||||
| 2026 | 2025 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash | $ | $ | ||||||
| Receivable from sale of equity method investment | ||||||||
| Deferred offering costs | ||||||||
| Prepaid expense and other current assets | ||||||||
| Current assets of discontinued operations | ||||||||
| Total Current Assets | ||||||||
| NON-CURRENT ASSETS: | ||||||||
| Deferred offering costs, net of current portion | ||||||||
| Operating lease right-of-use assets, net | ||||||||
| Property and equipment, net | ||||||||
| Intangible assets, net | ||||||||
| Goodwill | ||||||||
| Non-current assets of discontinued operations | ||||||||
| Total Non-current Assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accrued professional fees | $ | $ | ||||||
| Accrued research and development fees | ||||||||
| Accrued payroll liability and compensation | ||||||||
| Accrued litigation settlement | ||||||||
| Accrued liabilities and other payables | ||||||||
| Accrued liabilities and other payables - related party | ||||||||
| Operating lease obligation | ||||||||
| Advance from pending sale of subsidiary - related party | ||||||||
| Derivative liability | ||||||||
| Stock subscription liability | ||||||||
| Bridge loan payable, net | ||||||||
| Convertible note payable, net | ||||||||
| Note payable, net | ||||||||
| Series F Convertible Redeemable Preferred Stock, net | ||||||||
| Current liabilities of discontinued operations | ||||||||
| Total Current Liabilities | ||||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Operating lease obligation, net of current portion | ||||||||
| Non-current liabilities of discontinued operations | ||||||||
| Total Non-current Liabilities | ||||||||
| Total Liabilities | ||||||||
| Commitments and Contingencies (Note 17) | ||||||||
| EQUITY: | ||||||||
| Preferred stock, $ | ||||||||
| Series C Convertible Preferred Stock, | ||||||||
| Series D Convertible Preferred Stock, | ||||||||
| Series E Convertible Preferred Stock, | ||||||||
| Liquidation preference $ | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Less: common stock held in treasury, at cost; | ( | ) | ( | ) | ||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Statutory reserve | ||||||||
| Accumulated other comprehensive loss | ( | ) | ( | ) | ||||
| Total Change Agents Corporation stockholders’ equity | ||||||||
| Noncontrolling interest | ||||||||
| Total Equity | ||||||||
| Total Liabilities and Equity | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
1
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| For the Three Months Ended | For the Nine Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO | $ | $ | $ | $ | ||||||||||||
| OTHER OPERATING EXPENSES: | ||||||||||||||||
| Advertising and marketing expenses | ||||||||||||||||
| Professional fees | ||||||||||||||||
| Compensation and related benefits | ||||||||||||||||
| Amortization of intangible assets | ||||||||||||||||
| Credit loss expense | ( | ) | ||||||||||||||
| Other general and administrative expenses | ||||||||||||||||
| Total Other Operating Expenses | ||||||||||||||||
| LOSS FROM OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| OTHER INCOME (EXPENSE) | ||||||||||||||||
| Interest expense - amortization of debt discount and debt issuance costs | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense - other | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Change in fair value of derivative liability | ( | ) | ( | ) | ||||||||||||
| Loss on extinguishment of debt | ( | ) | ||||||||||||||
| Other (expense) income | ( | ) | ( | ) | ||||||||||||
| Total Other (Expense) Income, net | ( | ) | ( | ) | ( | ) | ||||||||||
| LOSS BEFORE INCOME TAXES | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| INCOME TAXES | ||||||||||||||||
| NET LOSS FROM CONTINUING OPERATIONS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| NET LOSS FROM DISCONTINUED OPERATIONS | ( | ) | ( | ) | ( | ) | ||||||||||
| NET LOSS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | ||||||||||||||||
| NET LOSS AFTER NONCONTROLLING INTEREST | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS | ||||||||||||||||
| NET LOSS ATTRIBUTABLE TO CHANGE AGENTS CORPORATION COMMON SHAREHOLDERS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| NET LOSS PER COMMON SHARE ATTRIBUTABLE TO CHANGE AGENTS CORPORATION COMMON SHAREHOLDERS: | ||||||||||||||||
| Basic and diluted, continuing operations | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic and diluted, discontinued operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Basic and diluted | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||||||||||||||
| Basic and diluted | ||||||||||||||||
| COMPREHENSIVE LOSS: | ||||||||||||||||
| NET LOSS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| OTHER COMPREHENSIVE (LOSS) INCOME FROM CONTINUED OPERATIONS | ||||||||||||||||
| Unrealized foreign currency translation (loss) gain | ( | ) | ( | ) | ||||||||||||
| COMPREHENSIVE LOSS | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | ||||||||||||||||
| COMPREHENSIVE LOSS ATTRIBUTABLE TO CHANGE AGENTS CORPORATION COMMON SHAREHOLDERS | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
See accompanying notes to the condensed consolidated financial statements.
2
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
For the Three and Nine Months Ended September 30, 2026
(Unaudited)
| Change Agents Corporation Stockholders’ Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series C Preferred Stock | Series D Preferred Stock | Series E Preferred Stock | Common Stock | Treasury Stock | Accumulated | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number | Number | Number | Number | Additional | Number | Other | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| of | of | of | of | Paid-in | of | Accumulated | Statutory | Comprehensive | Noncontrolling | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Reserve | Loss | Interest | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of pre-funded stock warrants | - | - | - | ( | ) | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of stock warrants | - | - | - | ( | ) | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series C Preferred Stock into common stock | ( | ) | ( | ) | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of convertible note payable and accrued interest into common stock | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of derivative liability to equity | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sales of securities from the February 2026 private placement, net | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of subsidiary (Note 3) | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2026 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cash exercise of pre-funded stock warrants | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series C Preferred Stock into common stock | ( | ) | ( | ) | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series D Preferred Stock into common stock | - | ( | ) | ( | ) | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series E Preferred Stock into common stock | - | - | ( | ) | ( | ) | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock as bridge loan payable commitment fee | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon waiver to enter into note agreement | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2026 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2026 | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cash exercise of pre-funded stock warrants | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of pre-funded stock warrants | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of pre-funded warrants for Equity Line of Credit (ELOC) commitment fee | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of pre-funded warrants as note payable inducement | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of pre-funded warrants for note payable one-time waiver | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Adjustment for options issued for service | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of Series E Preferred Stock into common stock | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock as note payable commitment fee | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock in respect of a most favored nations provision granted to noteholder | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock as Series F Preferred Stock commitment fee | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares issued for adjustments for 1:20 reverse split | - | - | - | - | - | - | ( | ) | - | - | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2026 | - | - | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2026 | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | $ | |||||||||||||||||||||||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements.
3
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN (DEFICIT) EQUITY
For the Three and Nine Months Ended September 30, 2025
(Unaudited)
| Change Agents Corporation Stockholders’ (Deficit) Equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series A Preferred Stock | Series B Preferred Stock | Series C Preferred Stock | Series D Preferred Stock | Common Stock | Treasury Stock | Accumulated | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Number | Number | Number | Number | Number | Additional | Number | Other | Total | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| of | of | of | of | of | Paid-in | of | Accumulated | Statutory | Comprehensive | Noncontrolling | Equity | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Shares | Amount | Capital | Shares | Amount | Deficit | Reserve | Loss | Interest | (Deficit) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, January 1, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | $ | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of stock warrants | - | - | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of derivative liability to equity | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock | ( | ) | ( | ) | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Series B Convertible Preferred Stock extinguished related to sale of equity method investment | - | ( | ) | ( | ) | - | - | - | - | ( | ) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended March 31, 2025 | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock upon cashless exercise of stock warrants | - | - | - | - | ( | ) | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassification of derivative liability to equity | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation adjustment | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of convertible note payable and accrued interest into common stock | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Loss on extinguishment of debt recognized | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended June 30, 2025 | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, June 30, 2025 | ( | ) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of Series C Convertible Preferred Stock, net | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sale of common stock and warrants, net | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock for services | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Conversion of convertible note payable and accrued interest into common stock | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Issuance of common stock as convertible note payable commitment fee | - | - | - | - | - | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Foreign currency translation adjustment | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net loss for the three months ended September 30, 2025 | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||||||||||||||||||||||||||||
See accompanying notes to the condensed consolidated financial statements.
4
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| For the Nine Months Ended | ||||||||
| September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss from continuing operations | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization of intangible assets | ||||||||
| Amortization of operating lease right-of-use asset | ||||||||
| Stock-based compensation and service expense | ||||||||
| Income from equity method investment | ( | ) | ||||||
| Amortization of debt issuance costs and debt discount | ||||||||
| Non-cash interest expense | ||||||||
| Change in fair market value of derivative liability | ( | ) | ||||||
| Loss on extinguishment of debt | ||||||||
| Changes in operating assets and liabilities: | ||||||||
| Deferred offering costs | ||||||||
| Security deposit | ||||||||
| Prepaid expense and other assets | ( | ) | ||||||
| Accrued liabilities and other payables | ||||||||
| Operating lease obligation | ( | ) | ( | ) | ||||
| NET CASH USED IN OPERATING ACTIVITIES FROM CONTINUING OPERATIONS | ( | ) | ( | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Proceeds from sale of equity method investment | ||||||||
| Purchase of property and equipment | ( | ) | ||||||
| Acquisition of internal-use software | ( | ) | ||||||
| NET CASH PROVIDED BY INVESTING ACTIVITIES FROM CONTINUING OPERATIONS | ||||||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Repayments of bridge loan | ( | ) | ||||||
| Repayments of convertible debt | ( | ) | ||||||
| Proceeds from issuance of convertible debt | ||||||||
| Proceeds from issuance of debt | ||||||||
| Payments of debt issuance costs | ( | ) | ||||||
| Repayments of debt | ( | ) | ||||||
| Proceeds from issuance of Series F Convertible Preferred Stock | ||||||||
| Proceeds from stock subscription liability | ||||||||
| Advance from pending sale of subsidiary | ||||||||
| Proceeds from issuance of convertible preferred stock | ||||||||
| Payments of convertible preferred stock issuance costs | ( | ) | ||||||
| Proceeds from issuance of common stock and warrants | ||||||||
| Payments of offering costs | ( | ) | ( | ) | ||||
| Proceeds from warrant exercises | ||||||||
| Proceeds received from the February 2026 private offering | ||||||||
| Disbursements for the February 2026 private offering costs | ( | ) | ||||||
| NET CASH PROVIDED BY FINANCING ACTIVITIES FROM CONTINUING OPERATIONS | ||||||||
| DISCONTINUED OPERATIONS | ||||||||
| Net cash used in operating activities from discontinued operations | ( | ) | ( | ) | ||||
| Net cash used in investing activities from discontinued operations | ( | ) | ||||||
| NET CASH FLOWS USED IN DISCONTINUED OPERATIONS | ( | ) | ( | ) | ||||
| EFFECT OF EXCHANGE RATE ON CASH - CONTINUING OPERATIONS | ||||||||
| NET INCREASE (DECREASE) IN CASH | ( | ) | ||||||
| CASH - beginning of period | ||||||||
| CASH - end of period | $ | $ | ||||||
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | ||||||||
| Cash paid for: | ||||||||
| Interest | $ | $ | ||||||
| NON-CASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Common stock issued for future services | $ | $ | ||||||
| Common stock issued for accrued liabilities | $ | $ | ||||||
| Options issued for accrued liabilities | $ | $ | ||||||
| Receivable related to sale of equity method investment | $ | $ | ||||||
| Related party payable extinguished upon sale of equity method investment | $ | $ | ||||||
| Series B Convertible Preferred Stock extinguished related to sale of equity method investment | $ | $ | ||||||
| Series D Convertible Preferred Stock issued in exchange of Series A Convertible Preferred Stock | $ | $ | ||||||
| Stock warrants issued as placement agent fee | $ | $ | ||||||
| Common stock issued as convertible note payable commitment fee | $ | $ | ||||||
| Settlement of derivative liability | $ | $ | ||||||
| Issuance of common stock upon cashless exercise of stock warrants | $ | $ | ||||||
| Issuance of common stock upon cashless exercise of pre-funded stock warrants | $ | $ | ||||||
| Initial ROU asset and lease liability | $ | $ | ||||||
| Conversion of convertible note payable and accrued interest into common stock | $ | $ | ||||||
| Series C Convertible Preferred Stock converted into common stock | $ | $ | ||||||
| Series D Convertible Preferred Stock converted into common stock | $ | $ | ||||||
| Series E Convertible Preferred Stock converted into common stock | $ | $ | ||||||
| Related party gain on deconsolidation of Avalon RT 9 | $ | $ | ||||||
| Deferred financing costs in accrued liabilities | $ | $ | ||||||
| Issuance of common stock upon waiver to enter into note agreement | $ | $ | ||||||
| Legal fees recorded to receivable from sale of equity method investment | $ | $ | ||||||
| Pre-funded warrants issued for Equity Line of Credit (ELOC) commitment fee | $ | $ | ||||||
| Pre-funded warrants issued as note payable inducement | $ | $ | ||||||
| Common stock issued for note payable commitment fee | $ | $ | ||||||
See accompanying notes to the condensed consolidated financial statements.
5
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS
Change Agents Corporation (f/k/a Avalon GloboCare Corp.) (the “Company” or “CHGA”) was incorporated under the laws of the State of Delaware on
The Company operates through two business segments: (i) an artificial intelligence software segment, through which the Company develops and commercializes an AI-driven, short-form agentic video generation platform and an agentic Generative Engine Optimization (GEO) search product operated by Avalon Quantum AI, LLC, a wholly owned subsidiary formed in connection with the acquisition of RPM Interactive, Inc. in December 2025; and (ii) a consumer health technology segment, through which the Company distributes the Keto Air breathalyzer device - a non-invasive consumer breathalyzer that measures ketosis levels and is sold in North America, bearing an FDA registration number.
The Company is a technology-focused company with a strategic focus on developing innovative Agentic AI software and consumer health products that target consumers and small businesses. The Company recently announced the intent to expand into drone interception and surveillance AI enhanced technology solutions through the establishment of Autonomous Air Defense Systems LLC. The Company is actively seeking complementary bolt-on AI acquisitions that could generate near-term revenue to supplement current operations as both segments continue to develop.
On May 18, 2015, Avalon Healthcare System, Inc. (“AHS”) was incorporated under the laws of the State of Delaware. AHS owns
On February 7, 2017, the Company formed Avalon RT 9 Properties, LLC (“Avalon RT 9”), a New Jersey limited liability company. On May 5, 2017, Avalon RT 9 purchased a real property located in Township of Freehold, County of Monmouth, State of New Jersey, having a street address of 4400 Route 9 South, Freehold, NJ 07728. This property was purchased to serve as the Company’s world-wide headquarters for all corporate administration and operations. In addition, the property generates rental income. Avalon RT 9 owns this office building. Avalon RT 9’s business consists of the ownership and operation of the income-producing real estate property in New Jersey. On February 18, 2026, the Company sold
On October 14, 2022, the Company formed a wholly owned subsidiary, Avalon Laboratory Services, Inc. (“Avalon Lab”), a Delaware company. On February 9, 2023, Avalon Lab purchased
On May 1, 2024, the Company formed a wholly owned subsidiary, Q&A Distribution LLC (“Q&A Distribution”), a Texas company. Q&A Distribution is engaged in distribution of KetoAir device.
On February 21, 2025, the Company formed a wholly owned subsidiary, Nexus MergerSub Limited (“Nexus”), a British Virgin Islands (“BIV”) company. There was no activity for the subsidiary since its incorporation through September 30, 2026.
On December 5, 2025, the Company formed a wholly owned subsidiary, Avalon Quantum AI, LLC (“Avalon Quantum AI”), a Nevada company.
On December 12, 2025, the Company acquired RPM Interactive, Inc., a Nevada corporation (“RPM”), in accordance with the terms of the Agreement and Plan of Merger, dated December 12, 2025, as amended by Amendment No. 1 dated December 14, 2025 (as amended, the “Merger Agreement”), by and among the Company, Avalon Quantum AI, LLC, a Nevada limited liability company and a wholly owned subsidiary of the Company (the “Merger Sub”), and RPM. Pursuant to the Merger Agreement, RPM merged with and into the Merger Sub, pursuant to which the Merger Sub was the surviving entity and became a wholly owned subsidiary of the Company (the “Merger”).
6
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS (continued)
As a result of the above Merger transaction, effective December 12, 2025, Avalon Quantum AI is advancing next-generation AI systems, including automated video generation, and small business marketing automation solutions.
On August 4, 2026, the Company formed a wholly owned subsidiary, Autonomous Air Defense Systems LLC, a Delaware company. There was no activity for the subsidiary since its incorporation through September 30, 2026.
Details of the Company’s subsidiaries which are included in these condensed consolidated financial statements as of September 30, 2026 are as follows:
| Name of Subsidiary | Place and Date of Incorporation | Percentage of Ownership | Principal Activities | |||
| Avalon Healthcare System, Inc. (“AHS”) | May 18, 2015 | CHGA | ||||
| Avalon (Shanghai) Healthcare Technology Co., Ltd. (“Avalon Shanghai”) | April 29, 2016 | AHS | ||||
| Genexosome Technologies Inc. (“Genexosome”) | July 31, 2017 | CHGA | ||||
| Avalon Laboratory Services, Inc. (“Avalon Lab”) | October 14, 2022 | CHGA | ||||
| Q&A Distribution LLC (“Q&A Distribution”) | May 1, 2024 | CHGA | ||||
| Nexus MergerSub Limited (“Nexus”) | February 21, 2025 | CHGA | ||||
| Avalon Quantum AI, LLC (“Avalon Quantum AI”) | December 5, 2025 | CHGA | ||||
| Autonomous Air Defense Systems LLC | CHGA |
NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN CONDITION
Basis of Presentation
These interim condensed consolidated financial statements of the Company and its subsidiaries are unaudited. In the opinion of management, all adjustments (consisting of normal recurring accruals) and disclosures necessary for a fair presentation of these interim condensed consolidated financial statements have been included. The results reported in the condensed consolidated financial statements for any interim periods are not necessarily indicative of the results that may be reported for the entire year. The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and do not include all information and footnotes necessary for a complete presentation of financial statements in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”). The Company’s condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Certain information and footnote disclosures normally included in the annual consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the SEC on March 30, 2026.
7
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 2 – BASIS OF PRESENTATION AND GOING CONCERN CONDITION (continued)
Basis of Presentation (continued)
As of September 30, 2026, the Company determined that certain assets that had been disposed of met the criteria for discontinued operations presentation. For all periods presented, the operating results associated with the assets disposed of have been reclassified into net loss from discontinued operations in the Condensed Consolidated Statements of Operations and Comprehensive Loss. The associated assets and liabilities have been reflected as current and long-term assets and liabilities of discontinued operations in the Condensed Consolidated Balance Sheets, and the cash flows from the Company’s discontinued operations are presented in the Condensed Consolidated Statements of Cash Flows for all periods presented.
Certain prior period balances related to the Company’s reportable segments and discontinued operations have been reclassified to conform to the current presentation in the financial statements and accompanying notes. The notes to the Condensed Consolidated Financial Statements are presented on a continuing operations basis unless otherwise noted. Refer to Note 5 Discontinued Operations and Disposals for additional information on the Company’s discontinued operations.
Going Concern
These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business.
As reflected in the accompanying condensed consolidated financial statements, the Company had a working capital deficit of approximately $
The Company has a limited operating history and its continued growth is dependent upon the continuation of generating revenue for selling of Keto Air, generating revenue from advanced Agentic AI systems, including automated video generation and small business marketing automation, and obtaining additional financing to fund future obligations and pay liabilities arising from normal business operations. In addition, the current cash balance cannot be projected to cover the operating expenses for the next twelve months from the release date of this report. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital, implement its business plan, and generate significant revenue. There are no assurances that the Company will be successful in its efforts to generate significant revenue, maintain sufficient cash balance or report profitable operations or to continue as a going concern. The Company plans on raising capital through the sale of equity to implement its business plan. However, there is no assurance these plans will be realized and that any additional financings will be available to the Company on satisfactory terms and conditions, if any.
The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates
The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Significant estimates during the three and nine months ended September 30, 2026 and 2025 include the useful life of intangible assets, the assumptions used in assessing impairment of long-term assets, the allowance for credit loss, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation, the valuation of Series D convertible preferred stock (“Series D Preferred Stock”), and the determination of the fair value of the warrants.
8
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Cash and Cash Equivalents
At September 30, 2026 and December 31, 2025, the Company’s cash balances by geographic area were as follows:
| Country: | September 30, 2026 | December 31, 2025 | ||||||||||||||
| United States | $ | % | $ | % | ||||||||||||
| China | % | % | ||||||||||||||
| Total cash | $ | % | $ | % | ||||||||||||
For purposes of the condensed consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less when purchased and money market accounts to be cash equivalents. The Company had cash equivalents at September 30, 2026 and December 31, 2025.
Fair Value of Financial Instruments and Fair Value Measurements
The Company adopted the guidance of Accounting Standards Codification (“ASC”) 820 for fair value measurements which clarifies the definition of fair value, prescribes methods for measuring fair value, and establishes a fair value hierarchy to classify the inputs used in measuring fair value as follows:
| ● | Level 1-Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. |
| ● | Level 2-Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. |
| ● | Level 3-Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. |
The fair value of the Company’s assets and liabilities, which qualify as financial instruments under ASC Topic 820, “Fair Value Measurement,” approximates the carrying amounts represented in the accompanying condensed consolidated financial statements, primarily due to their short-term nature.
Assets and liabilities measured at fair value on a recurring basis. Certain assets and liabilities are measured at fair value on a recurring basis. These assets and liabilities are measured at fair value on an ongoing basis. These assets and liabilities include derivative liability.
Derivative liability. Derivative liability is carried at fair value and measured on an ongoing basis.
| Significant Unobservable Inputs (Level 3) | ||||
| Balance of derivative liability as of January 1, 2026 | $ | |||
| Loss from change in the fair value of derivative liability | ||||
| Reclassification of additional paid-in capital upon conversion | ( | ) | ||
| Balance of derivative liability as of September 30, 2026 | $ | |||
ASC 825-10 “Financial Instruments”, allows entities to voluntarily choose to measure certain financial assets and liabilities at fair value (fair value option). The fair value option may be elected on an instrument-by-instrument basis and is irrevocable, unless a new election date occurs. If the fair value option is elected for an instrument, unrealized gains and losses for that instrument should be reported in earnings at each subsequent reporting date. The Company did not elect to apply the fair value option to any outstanding instruments.
9
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Credit Risk and Uncertainties
The Company maintains a portion of its cash on deposits with bank and financial institution within the U.S. that at times may exceed federally-insured limits of $
Sale of Subsidiary
In February 2026, the Company sold its wholly-owned subsidiary of Avalon RT 9 to Wenzhao Lu, the Company’s chairman of the Board of Directors. Avalon RT 9 owned and managed the corporate office building located at 4400 Route 9 South, Freehold, NJ, which served as the Company’s headquarters and leased other space to tenants until the sale. Mr. Lu paid fair value of $
Deferred Offering Costs
Deferred offering costs consist of legal, accounting, Equity Line of Credit (“ELOC”) commitment fee, and other costs that are directly related to the Company’s equity financing and will be charged to stockholders’ equity upon completion of the equity offering. As of September 30, 2026 and December 31, 2025, deferred offering costs amounted to $
Software and Platform
The Company capitalizes costs to develop or purchase software and platform in accordance with ASC section 350-40, Intangibles — Goodwill and Other. Costs incurred to develop software and platform are expensed as incurred during the preliminary project stage. Software and platform development costs are capitalized upon purchase and during the application development stage, which is after: (i) the preliminary project stage is completed; and (ii) management authorizes and commits to funding the project and it is probable the project will be completed and used to perform the functions intended. Capitalization ceases at the point the software and platform project is substantially complete and ready for its intended use, and after all substantial testing is completed. Upgrades and enhancements are capitalized if it is probable that those expenditures will result in additional functionality. Amortization is provided for on a straight-line basis over the expected useful life of the software and platform development costs and related upgrades and enhancements. When existing software and platform are replaced with new software and platform, the unamortized costs of the old software and platform are expensed when the new software and platform are ready for its intended use.
Stock Subscription Liability
On June 4, 2025, the Company entered into a subscription agreement with an investor, whereby
Per Share Data
ASC Topic 260 “Earnings per Share,” requires presentation of both basic and diluted earnings per share (“EPS”) with a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. Basic EPS excludes dilution. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity.
10
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Per Share Data (continued)
Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during each period. The Company had $
The calculation of basic and diluted net loss per common share attributable to the Company common shareholders includes
The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Options to purchase common stock | ||||||||||||||||
| Warrants to purchase common stock | ||||||||||||||||
| Series C convertible preferred stock (*) | ||||||||||||||||
| Series D convertible preferred stock (**) | ||||||||||||||||
| Series E convertible preferred stock (***) | ||||||||||||||||
| Series F convertible preferred stock (****) | ||||||||||||||||
| Convertible notes and related accrued interest (*****) | ||||||||||||||||
| Potentially dilutive securities | ||||||||||||||||
| (*) |
| (**) |
| (***) |
| (****) |
| (*****) |
Commitments and Contingencies
In the normal course of business, the Company is subject to contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters. Liabilities for such contingencies are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.
11
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Segment Reporting
The segment reporting structure uses the Company’s management reporting structure as its foundation to reflect how the Company manages the businesses internally and was mainly organized by services. During the three and nine months ended September 30, 2026, the Company was organized into one strategic business units: AI generated publishing services. During the nine months ended September 30, 2025, the Company was organized into one strategic business units: laboratory testing services (which ended on the redemption date, February 26, 2025) — which were led by our strategic business unit managers. Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker (“CODM”) in deciding how to make operating decisions, allocate resources and assess performance.
On February 9, 2023, the Company purchased
On February 18, 2026, the Company and Wenzhao Lu, the Company’s chairman of the Board of Directors, entered into an Amended and Restated Membership Interest Purchase Agreement, pursuant to which the Company sold to Mr. Lu
Reverse Stock Split
The Company effectuated a
Reclassification
Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications have no effect on the previously reported financial position, results of operations and cash flows.
Recent Accounting Standards
In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. In January 2025, the FASB issued ASU No. 2025-01, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40), Clarifying the Effective Date. ASU 2024-03 requires public companies to disclose, in interim and reporting periods, additional information about certain expenses in the financial statements. ASU 2024-03, as clarified by ASU 2025-01, is effective for public entities for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and is effective on either a prospective basis or retrospective basis. The Company is currently evaluating the impact that the updated standard will have on the Company’s disclosures within the condensed consolidated financial statements.
12
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)
Recent Accounting Standards (continued)
In September 2025, the FASB issued Accounting Standards Update No. 2025-06, “Intangibles — Goodwill and Other — Internal-Use Software (Subtopic 350-40),” (“ASU 2025-06”). The amendments in ASU 2025-06 remove all references to prescriptive and sequential software development stages, and require entities to start capitalizing software costs when management has authorized and committed to funding the software project and it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027, and interim periods within those fiscal years, and may be adopted on a prospective, modified, or retrospective transition approach. Early adoption is permitted. The Company is currently evaluating the impact of this update on its condensed consolidated financial statements.
In December 2025, the FASB issued ASU 2025–11, Interim Reporting (Topic 270: Narrow – Scope Improvements. ASU 2025-11 clarifies the applicability of interim reporting guidance and reorganizes and clarifies interim disclosure requirements under ASC topic 270, including the addition of a disclosure principal requiring disclosure of material events occurring since the most recent annual reporting period. ASU 2025-11 is effective for interim reporting periods within annual periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.
In December 2025, the FASB issued ASU 2025-12, Classification Improvements. ASU 2025–12 makes targeted amendments to various topics within the Accounting Standards Codification intended to clarify existing guidance and correct minor inconsistencies. ASU 2025–12 is effective for interim and annual reporting periods beginning after December 15, 2026, with early adoption permitted. Certain amendments require retrospective application. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.
Other accounting standards that have been issued or proposed by FASB that do not require adoption until a future date are not expected to have a material impact on the condensed consolidated financial statements upon adoption. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its condensed consolidated financial condition, results of operations, cash flows or disclosures.
NOTE 4 – PREPAID EXPENSE AND OTHER CURRENT ASSETS
At September 30, 2026 and December 31, 2025, prepaid expense and other current assets consisted of the following:
| September 30, 2026 | December 31, 2025 | |||||||
| Prepaid professional fees | $ | $ | ||||||
| Prepaid directors’ and officers’ liability insurance premium | ||||||||
| Prepaid NASDAQ listing fee | ||||||||
| Finished goods | ||||||||
| Recoverable value-added tax | ||||||||
| Others | ||||||||
| Total | $ | $ | ||||||
NOTE 5 – DISCONTINUED OPERATIONS AND DISPOSALS
On February 18, 2026, the Company and Wenzhao Lu, the Company’s chairman of the Board of Directors, entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), pursuant to which the Company sold to Mr. Lu
The subsidiary comprises our real property operations segment. As a result of the planned disposition of the subsidiary, the real property operations segment met the criteria under ASC 205-20 to be classified as discontinued operations. Accordingly, the historical results of operations of the real property operations segment have been reflected as discontinued operations in our condensed consolidated financial statement for all periods prior to the Amended MIPA on February 18, 2026.
13
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 5 – DISCONTINUED OPERATIONS AND DISPOSALS (continued)
The table below outlines the gain on sale described above:
| Carrying amount of assets and liabilities: | ||||
| Cash | $ | |||
| Rent receivable | ||||
| Prepaid expense | ||||
| Deferred leasing costs | ||||
| Property and equipment, net | ||||
| Investment in real estate, net | ||||
| Accrued liabilities | ||||
| Tenants’ security deposit | ||||
| Total carrying amount (net) | ||||
| Consideration from sale of subsidiary | ||||
| Gain on sale of subsidiary | $ | |||
The Company recorded the gain on sale of subsidiary of $
Details of the net loss from discontinued operations were as follows:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| REAL PROPERTY RENTAL REVENUE | $ | $ | $ | $ | ||||||||||||
| REAL PROPERTY OPERATING EXPENSES | ( | ) | ( | ) | ( | ) | ||||||||||
| REAL PROPERTY OPERATING INCOME | ||||||||||||||||
| OTHER OPERATING EXPENSES: | ||||||||||||||||
| Professional fees | ||||||||||||||||
| Compensation and related benefits | ||||||||||||||||
| Total Other Operating Expenses | ||||||||||||||||
| INCOME FROM OPERATIONS | ||||||||||||||||
| OTHER (EXPENSE) INCOME | ||||||||||||||||
| Interest expense - amortization of debt discount and debt issuance costs | ( | ) | ( | ) | ||||||||||||
| Interest expense - other | ( | ) | ( | ) | ( | ) | ||||||||||
| Other income | ||||||||||||||||
| Total Other Expense, net | ( | ) | ( | ) | ( | ) | ||||||||||
| LOSS BEFORE INCOME TAXES | ( | ) | ( | ) | ( | ) | ||||||||||
| INCOME TAXES | ||||||||||||||||
| NET LOSS | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
14
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 5 – DISCONTINUED OPERATIONS AND DISPOSALS (continued)
The following table summarizes the assets and liabilities of the discontinued operations:
| September 30, 2026 | December 31, 2025 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash | $ | $ | ||||||
| Rent receivable | ||||||||
| Prepaid expense and other current assets | ||||||||
| Total Current Assets | ||||||||
| NON-CURRENT ASSETS: | ||||||||
| Property and equipment, net | ||||||||
| Investment in real estate, net | ||||||||
| Deferred leasing costs and other non-current assets | ||||||||
| Total Non-current Assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accrued liabilities and other payables | $ | $ | ||||||
| Note payable, net | ||||||||
| Total Current Liabilities | ||||||||
| NON-CURRENT LIABILITIES: | ||||||||
| Deferred rental income | ||||||||
| Total Non-current Liabilities | ||||||||
| Total Liabilities | $ | $ | ||||||
The above tables exclude intercompany payables that are eliminated within our condensed consolidated balance sheets.
NOTE 6 – INTANGIBLE ASSETS
Intangible assets mainly consist of the valuation of identifiable intangible assets acquired in connection with the acquisition of RPM, representing developed technology and trade name. The Company uses its best estimates and assumptions as part of the purchase price allocation process to accurately value the identifiable intangible assets at the acquisition date. The straight-line method of amortization represents the Company’s best estimate of the distribution of the economic value of the identifiable intangible assets.
In addition, in connection with the acquisition of RPM, the purchase price exceeded the fair value of net assets acquired by $
During the three and nine months ended September 30, 2026, the Company capitalized certain software and platform development costs incurred amounting to $
15
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 6 – INTANGIBLE ASSETS (continued)
At September 30, 2026 and December 31, 2025, intangible assets consisted of the following:
| Useful Life | September 30, 2026 | December 31, 2025 | ||||||||
| Developed technology | $ | $ | ||||||||
| Trade name | ||||||||||
| Software and platform | ||||||||||
| Goodwill | ||||||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||||
| $ | $ | |||||||||
For the three months ended September 30, 2026 and 2025, amortization expense amounted to $
Amortization of intangible assets, excluding software and platform, which have not yet been placed in service as of September 30, 2026, attributable to future periods is as follows:
| For the Twelve-month Period Ending September 30: | Amortization Amount | |||
| 2027 | $ | |||
| 2028 and thereafter | ||||
| $ | ||||
NOTE 7 – CONVERTIBLE NOTE PAYABLE, NET
June 2024 Convertible Note
On June 5, 2024, the Company entered into securities purchase agreements with Mast Hill for the issuance of
Mast Hill acquired the June 2024 Convertible Note with principal amount of $
On December 15, 2024, the Company and Mast Hill entered into that certain consent, acknowledgement, and waiver agreement, pursuant to which Mast Hill waived all amortization payments required to be made under the June 2024 Convertible Note, the Company paid a waiver fee of $
16
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 7 – CONVERTIBLE NOTE PAYABLE NET (continued)
June 2024 Convertible Note (continued)
On May 29, 2025, the Company and Mast Hill entered into that certain waiver (the “Waiver”), pursuant to which Mast Hill will retain all related dilutive issuance rights under Section 1.6(e) of the June 2024 Convertible Note, provided that any adjustment under Section 1.6(e) of the June 2024 Convertible Note shall be subject to a per share floor price equal to $
In December 2024, the Company repaid June 2024 Convertible Note principal amount of $
During the period from June 1, 2025 through December 31, 2025, Mast Hill converted its June 2024 Convertible Note in the principal amount of $
In January 2026, Mast Hill converted its June 2024 Convertible Note in the principal amount of $
July 2025 Convertible Note
On July 3, 2025, the Company issued two convertible promissory notes (“July 2025 Convertible Note”) to two accredited investors on identical terms. The July 2025 Convertible Note has a principal amount of $
Pursuant to the terms of the July 2025 Convertible Note, beginning six months after the issue date, the two investors may convert the outstanding principal and accrued interest into shares of the Company’s common stock at a fixed conversion price of $
As consideration for the two investors’ purchase of the July 2025 Convertible Note, the Company issued
In March 2026, the Company repaid in full the July 2025 Convertible Note.
The convertible notes payable as of September 30, 2026 and December 31, 2025 was as follows:
| September 30, 2026 | December 31, 2025 | |||||||
| Principal amount | $ | $ | ||||||
| Less: unamortized debt discount | ( | ) | ||||||
| Convertible note payable, net | $ | $ | ||||||
For the three months ended September 30, 2026 and 2025, amortization of debt discount related to convertible note payable amounted to $
For the three months ended September 30, 2026 and 2025, interest expense related to convertible note payable amounted to $
17
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 8 – BRIDGE LOAN PAYABLE, NET
On December 11, 2025, the Company entered into a securities purchase agreement with Allen O Cage Jr., an individual, pursuant to which the Company issued an unsecured bridge note with a maturity date of
On February 15, 2026, the Company entered into Amendment (the “Note Amendment”) to unsecured bridge note. The Note Amendment extended the time periods under the bridge note for the first payment deadline, the second payment deadline and third payment deadline as follows: (i) the first payment deadline under this Note Amendment is extended to March 16, 2026 from February 15, 2026; the second payment deadline under the Note Amendment is extended to April 15, 2026 from March 15, 2026 and (iii) the third payment deadline under the Note Amendment is extended to May 15, 2026 from April 15, 2026.
In connection with the issuance of the bridge note, the Company incurred debt issuance costs of $
In accordance with ASC 480-10-25-14, the Company determined that the conversion provisions contain an embedded derivative feature and the Company valued the derivative feature separately, recording debt discount and derivative liability in accordance with the provisions of the bridge note. However, management determined the probability of occurrence of an event of default under the bridge note was remote and as such the fair value of the embedded conversion feature had been estimated to be zero.
The Company recorded a total debt discount of $
In March and April 2026, the Company repaid in full the bridge note.
The bridge loan payable as of September 30, 2026 and December 31, 2025 was as follows:
| September 30, 2026 | December 31, 2025 | |||||||
| Principal amount | $ | $ | ||||||
| Less: unamortized debt issuance costs | ( | ) | ||||||
| Less: unamortized debt discount | ( | ) | ||||||
| Convertible note payable, net | $ | $ | ||||||
For the three months ended September 30, 2026, amortization of debt discount and debt issuance costs related to the bridge note amounted to $
For the nine months ended September 30, 2026, amortization of debt discount and debt issuance costs related to the bridge note amounted to $
18
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 9 – NOTE PAYABLE, NET
In February 2026, the Company entered into two securities purchase agreements with Vanquish Funding Group, Inc., pursuant to which the Company issued to the investor two promissory notes in the principal amount of $
On March 25, 2026, the Company entered into a Business Loan and Security Agreement (the “March 2026 Business Loan Agreement”) with Agile Lending LLC, pursuant to which the Company obtained a loan from the investor in the principal amount of $
On June 1, 2026, the Company issued promissory note to Dune Equity Holdings LLC (“Dune”) in the principal amount of $
On June 2, 2026, the Company issued promissory note to FirstFire Global Opportunities Fund, LLC (“FirstFire”) in the principal amount of $
On July 24, 2026, the Company entered into a Business Loan and Security Agreement (the “July 2026 Business Loan Agreement”) with Agile Lending LLC and the Company’s subsidiaries, Avalon Healthcare System inc., a Delaware corporation, Avalon Laboratory Services, Inc., a Delaware corporation and Avalon Quantum AI LLC, a Delaware limited liability company (individually and collectively, jointly and severally, “Guarantors”), pursuant to which the Company obtained a loan from the investor in the principal amount of $
19
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 9 – NOTE PAYABLE, NET (continued)
On August 13, 2026, the Company issued promissory note to FirstFire in the principal amount of $
On August 14, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
On September 8, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
On September 28, 2026, the Company’s Chief Strategy Officer (CSO), Luisa Ingargiola, advanced the Company $
On September 30, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
In the nine months ended September 30, 2026, the Company repaid an aggregate of $
The note payable as of September 30, 2026 is as follows:
| September 30, 2026 | ||||
| Principal amount | $ | |||
| Less: unamortized debt issuance costs | ( | ) | ||
| Less: unamortized debt discount | ( | ) | ||
| Note payable, net | $ | |||
20
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 9 – NOTE PAYABLE, NET (continued)
For the three months ended September 30, 2026, amortization of debt discount and debt issuance costs related to note payable amounted to $
For the nine months ended September 30, 2026, amortization of debt discount and debt issuance costs related to note payable amounted to $
For the three months ended September 30, 2026, interest expense related to note payable amounted to $
For the nine months ended September 30, 2026, interest expense related to note payable amounted to $
NOTE 10 – SERIES F CONVERTIBLE REDEEMABLE PREFERRED STOCK, NET
On July 2, 2026, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series F Convertible Preferred Stock with the Secretary of State of the State of Delaware, designating
Stated Value and Ranking. Each share of Series F Preferred Stock has a stated value of $
Dividends. No dividends are payable on the Series F Preferred Stock, except for stock dividends or distributions for which adjustments are made to the conversion price.
Voting Rights. Holders of Series F Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law. However, for so long as any shares of Series F Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of Series F Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences or rights of the Series F Preferred Stock, (b) increase the number of authorized shares of Series F Preferred Stock, or (c) enter into any agreement with respect to any of the foregoing.
Liquidation Preference. Upon any liquidation, dissolution or winding-up of the Company, holders of Series F Preferred Stock are entitled to receive, prior to any distribution to holders of common stock, an amount equal to
Conversion Rights. Each share of Series F Preferred Stock is convertible, at the option of the holder, at any time after the Shareholder Approval is obtained, into shares of common stock at a conversion price of $
Anti-Dilution Adjustments. The conversion price is subject to proportional adjustment in the event of stock dividends, stock splits, reverse stock splits, combinations, reclassifications and similar events. In the event of any recapitalization, reorganization, consolidation, merger or sale of all or substantially all of the Company’s assets, holders of Series F Preferred Stock will be entitled to receive, upon conversion, the same kind and amount of stock, securities or other assets or property that holders of common stock would receive in connection with such transaction.
Mandatory Redemption. The Company is required to redeem
21
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 10 – SERIES F CONVERTIBLE REDEEMABLE PREFERRED STOCK, NET (continued)
On June 30, 2026, the Company entered into a securities purchase agreement with Allen O. Cage Jr., pursuant to which the Company agreed to issue and sell to Allen (i)
The Series F Convertible Redeemable Preferred Stock as of September 30, 2026 is as follows:
| September 30, 2026 | ||||
| Series F Convertible Redeemable Preferred Stock | $ | |||
| Less: unamortized debt discount | ( | ) | ||
| Series A Convertible Redeemable Preferred Stock, net | $ | |||
For both the three and nine months ended September 30, 2026, amortization of debt discount amounted to $
For the both three and nine months ended September 30, 2026, interest expense related to Series F Convertible Redeemable Preferred Stock amounted to $
NOTE 11 – DERIVATIVE LIABILITY
On May 23, 2023, the Company issued
On July 6, 2023, the Company issued
On October 9, 2023, the Company issued
On March 7, 2024, the Company issued
22
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 11 – DERIVATIVE LIABILITY (continued)
On June 5, 2024, the Company issued
On June 5, 2024, the Company issued
Change in fair value of the derivative liability are included as a component of total other expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The changes to the derivative liability resulted in an increase of $
NOTE 12 – RELATED PARTY TRANSACTIONS
Advance from Related Party
On September 28, 2026, the Company’s Chief Strategy Officer (CSO), Luisa Ingargiola, advanced the Company $
On October 13, 2026, the Company’s CSO advanced the Company $
Services Provided by Related Party
From time to time, Wilbert Tauzin, a former director of the Company, and his son provide consulting services to the Company. As compensation for professional services provided, the Company recognized consulting expenses of $
23
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 12 – RELATED PARTY TRANSACTIONS (continued)
Accrued Liabilities and Other Payables – Related Party
In 2017, the Company acquired Genexosome’s subsidiary, which was dissolved in 2022, for a cash payment of $
Membership Interest Purchase Agreement
On November 17, 2023, the Company entered into a Membership Interest Purchase Agreement with Mr. Lu, the Company’s chairman of the Board of Directors, pursuant to which (i) Mr. Lu will acquire from the Company
On February 18, 2026, the Company and Mr. Lu entered into an Amended and Restated Membership Interest Purchase Agreement (the “Amended MIPA”), pursuant to which the Company sold to Mr. Lu
The Company received $
Exchange Agreement
On February 18, 2026, the Company entered into an Exchange Agreement with its Chairman, Wenzhao Lu, under which it agreed to issue Mr. Lu
Office Space from Related Party
Commencing on March 1, 2026, the Company leases office space from Avalon RT 9, which is wholly owned by Wenzhao Lu, the Company’s chairman of the Board of Directors. For the three and nine months ended September 30, 2026, rent expense related to office leased from Avalon RT 9 amounted $
NOTE 13 – EQUITY
The Company is authorized to issue an aggregate of
Series C Convertible Preferred Stock
On December 13, 2024, the Company filed a certificate of designations of preferences, rights, and limitations of Series C Preferred Stock (the “Series C Certificate of Designations”) with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of
24
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Series C Convertible Preferred Stock (continued)
The Series C Preferred Stock shall rank (i) senior to the Company’s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series C Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series C Preferred Stock, (iii) pari passu with Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) subordinate to the Series A Preferred Stock of the Company.
Holders of the Series C Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series C Preferred Stock equal (on an as-if-converted-to-common-stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock.
Holders of the Series C Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of the Series C Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference to the Series C Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series C Preferred Stock and (iii) in preference and priority to the holders of the shares of common stock, an amount equal to
Each share of Series C Preferred Stock shall be convertible into common stock (the “Series C Conversion Shares”) at a conversion per share equal to $
In March 2026,
In May 2026,
As of September 30, 2026 and December 31, 2025,
Series D Convertible Preferred Stock
On January 6, 2025, the Company filed a certificate of designations of preferences, rights, and limitations of Series D Preferred Stock (the “Series D Certificate of Designations”) with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of
The Series D Preferred Stock shall rank (i) senior to the Company’s common stock and any other class or series of capital stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series D Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series D Preferred Stock, (iii) pari passu with the Series B Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) pari passu with the Series C Preferred Stock of the Company.
Holders of the Series D Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law.
25
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Series D Convertible Preferred Stock (continued)
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of the Series D Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference to the Series D Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series D Preferred Stock and (iii) in preference and priority to the holders of the shares of common stock, an amount equal to
Each share of Series D Preferred Stock shall be convertible into common stock (the “Series D Conversion Shares”) at a conversion per share equal to $
On May 6, 2026, the Company issued
As of September 30, 2026 and December 31, 2025,
Series E Convertible Preferred Stock
On December 12, 2025, the Company filed a certificate of designations of preferences, rights, and limitations of Series E Non-Voting Convertible Preferred Stock (the “Series E Certificate of Designations”) with the Department of State, Division of Corporations, of the State of Delaware, which provides for the designation of
The Series E Preferred Stock shall rank (i) senior to the Company’s Common Stock and any other class or series of capital stock of the Company created hereafter, the terms of which specifically provide that such class or series shall rank junior to the Series E Preferred Stock, (ii) pari passu with any class or series of capital stock of the Company created hereafter specifically ranking, by its terms, on par with the Series E Preferred Stock, (iii) pari passu with Series C Convertible Preferred Stock of the Company with respect to its rights, preferences and restrictions, and (iv) pari passu the Series D Convertible Preferred Stock of the Company.
Holders of the Series E Preferred Stock shall be entitled to receive, and the Company shall pay, dividends on shares of Series E Preferred Stock equal (on an as-if-converted-to-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the Common Stock.
Holders of the Series E Preferred Stock have no voting power except as otherwise required by the Delaware General Corporation Law. Notwithstanding the foregoing, in addition, as long as any shares of Series E Preferred Stock are outstanding, the Corporation shall not, without the affirmative vote of the Holders of a majority of the then outstanding shares of the Series E Preferred Stock, voting as a separate class, (a) alter or change adversely the powers, preferences or rights given to the Series E Preferred Stock in this Certificate of Designation, (b) increase the number of authorized shares of Series E Preferred Stock, (c) authorize or issue an additional class or series of capital stock that ranks senior to the Series E Preferred Stock with respect to the distribution of assets on liquidation, or (d) enter into any agreement with respect to any of the foregoing.
26
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Series E Convertible Preferred Stock (continued)
Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary (a “Liquidation”), the holders of the Series E Preferred Stock shall be entitled to receive out of the assets available for distribution to stockholders, (i) after and subject to the payment in full of all amounts required to be distributed to the holders of another class or series of stock of the Company ranking on liquidation prior and in preference to the Series E Preferred Stock, including the Series A Preferred Stock, (ii) ratably with any class or series of stock ranking on liquidation on parity with the Series E Preferred Stock and (iii) in preference and priority to the holders of the shares of Common Stock, an amount equal to the greater of (i)
Each share of Series E Preferred Stock shall be convertible into Common Stock (the “Conversion Shares”), at any time from and after May 12, 2026, or such earlier time as consented to by the Company in writing at the option of the Holder thereof, into that number of shares of Common Stock (subject to certain limitations, determined by dividing the Stated Value of such share of Series E Preferred Stock by the Conversion Price of $
In addition, the Company shall not issue any shares of Common Stock upon conversion of the Series E Preferred Stock or otherwise pursuant to the terms of the Series E Certificate of Designation if the issuance of such shares of Common Stock would exceed the aggregate number of shares of Common Stock which the Company may issue upon exercise or conversion (as the case may be) of the Series E Preferred Stock without breaching the Company’s obligations under the rules and regulations the listing rules of the Company’s Principal Market (the maximum number of shares of Common Stock which may be issued without violating such rules and regulations, the “Exchange Cap”), except that such limitation shall not apply in the event that the Company (A) obtains the approval of its stockholders as required by the applicable rules and regulations of the Principal Market for issuances of shares of Common Stock in excess of such amount (the “Stockholder Approval Date”) or (B) obtains a written opinion from outside counsel to the Company that such approval is not required, which opinion shall be reasonably satisfactory to the Required Holders (as defined in the Series E Certificate of Designation).
In May 2026,
In August 2026,
As of September 30, 2026 and December 31, 2025,
Common Shares and Warrants Sold for Cash from the February 2026 Private Offering
In February 2026, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i)
27
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Common Shares and Warrants Sold for Cash from the February 2026 Private Offering (continued)
Each Warrant has an exercise price of $
The Prefunded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $
As compensation to H.C. Wainwright & Co., LLC as the exclusive placement agent in connection with the Private Placement (the “Placement Agent”), the Company paid the Placement Agent a cash fee of
In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of February 26, 2026, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of Shares and the shares of Common Stock underlying the Pre-Funded Warrants and the Common Warrants no later than 45 days after the date of the Registration Rights Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 75 days following the date of the Registration Rights Agreement (or 90 days following the date of the Registration Rights Agreement in the event of a “full review” by the Securities and Exchange Commission).
The fair value of the Series A-1 Warrants was $
The fair value of the Series A-2 Warrants was $
The fair value of the Placement Agent Warrants was $
$
The direct costs related to the issuance of the common shares and these warrants were $
28
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Common Shares Issued for Services
During the nine months ended September 30, 2026, the Company issued a total of
Common Shares Issued for Pre-funded Warrant Cashless Exercise
In January 2026, the Company issued an aggregate of
In July 2026, the Company issued
Common Shares Issued for Warrant Cashless Exercise
In February 2026, pursuant to the terms of related warrant agreements, the Company issued an aggregate of
Common Shares Issued for Pre-funded Warrant Cash Exercise
In April and June 2026, the Company issued an aggregate of
In July and August 2026, the Company issued an aggregate of
Common Shares Issued for Debt Conversion
In January 2026, the June 2024 Convertible Note holder converted its June 2024 Convertible Note in the principal amount of $
Common Shares Issued for Accrued Bridge Loan Payable Commitment Fee
In June 2026, the Company issued
Common Shares Issued upon Waiver to Enter into Note Agreement
In June 2026, the Company issued
Common Shares Issued for Note Payable Commitment Fee
In July and August 2026, the Company issued an aggregate of
29
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Common Shares Issued in respect of a most favored nations provision granted to noteholder
In September 2026, the Company issued
Common Shares Issued for Series F Convertible Preferred Stock Commitment Fee
In July 2026, the Company issued
Options
The following table summarizes the shares of the Company’s common stock issuable upon exercise of options outstanding at September 30, 2026:
| Options Outstanding | Options Exercisable | |||||||||||||||||||||
| Range of Exercise Price | Number Outstanding at September 30, 2026 | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | Number Exercisable at September 30, 2026 | Weighted Average Exercise Price | |||||||||||||||||
| $ | | $ | $ | |||||||||||||||||||
| $ | | $ | $ | |||||||||||||||||||
| $ | | $ | $ | |||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
Stock option activity for the nine months ended September 30, 2026 was as follows:
| Number of Options | Weighted Average Exercise Price | |||||||
| Outstanding at January 1, 2026 | $ | |||||||
| Granted | ||||||||
| Expired | ( | ) | ( | ) | ||||
| Outstanding at September 30, 2026 | $ | |||||||
| Options exercisable at September 30, 2026 | $ | |||||||
| Options expected to vest | $ | |||||||
The aggregate intrinsic value of both stock options outstanding and stock options exercisable at September 30, 2026 was $
The fair values of options granted during the nine months ended September 30, 2026 were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: volatility of
The fair values of options granted during the nine months ended September 30, 2025 were estimated at the date of grant using the Black-Scholes option-pricing model with the following assumptions: volatility of
30
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Options (continued)
For the three months ended September 30, 2026 and 2025, stock-based compensation expense associated with stock options granted amounted to $
For the nine months ended September 30, 2026 and 2025, stock-based compensation expense (adjustment) associated with stock options granted amounted to $
A summary of the status of the Company’s nonvested stock options granted as of September 30, 2026 and changes during the nine months ended September 30, 2026 is presented below:
| Number of Options | Weighted Average Exercise Price | |||||||
| Nonvested at January 1, 2026 | $ | |||||||
| Granted | ||||||||
| Vested | ( | ) | ( | ) | ||||
| Nonvested at September 30, 2026 | $ | |||||||
Warrants (Except Pre-Funded Warrants)
The following table summarizes the shares of the Company’s common stock issuable upon exercise of warrants outstanding at September 30, 2026:
| Warrants Outstanding | Warrants Exercisable | |||||||||||||||||||||
| Range of Exercise Price | Number Outstanding at September 30, 2026 | Weighted Average Remaining Contractual Life (Years) | Weighted Average Exercise Price | Number Exercisable at September 30, 2026 | Weighted Average Exercise Price | |||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
| $ | $ | $ | ||||||||||||||||||||
Stock warrant activity for the nine months ended September 30, 2026 was as follows:
| Number of Warrants | Weighted Average Exercise Price | |||||||
| Outstanding at January 1, 2026 | $ | |||||||
| Repricing adjustment | $ | |||||||
| Granted | $ | |||||||
| Exercised | ( | ) | $ | ( | ) | |||
| Outstanding at September 30, 2026 | $ | |||||||
| Exercisable at September 30, 2026 | $ | |||||||
The aggregate intrinsic value of both stock warrants outstanding and stock warrants exercisable at September 30, 2026 was approximately $
31
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Warrants (Except Pre-Funded Warrants) (continued)
Warrants Issued in February 2026
In February 2026, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i)
Each Warrant has an exercise price of $
The Prefunded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $
As compensation to H.C. Wainwright & Co., LLC as the exclusive placement agent in connection with the Private Placement (the “Placement Agent”), the Company paid the Placement Agent a cash fee of
In connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), dated as of February 26, 2026, with the Purchaser, pursuant to which the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) registering the resale of Shares and the shares of Common Stock underlying the Pre-Funded Warrants and the Common Warrants no later than 45 days after the date of the Registration Rights Agreement, and to use best efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 75 days following the date of the Registration Rights Agreement (or 90 days following the date of the Registration Rights Agreement in the event of a “full review” by the Securities and Exchange Commission).
These warrants were classified in shareholders’ equity as the number of shares were fixed and determinable, and no other provisions precluded equity treatment.
Warrants Exercised in February 2026
In February 2026, pursuant to the terms of related warrant agreements,
32
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Pre-Funded Warrants
The number of pre-funded warrants outstanding as of September 30, 2026 is as follows:
| Description | Number Outstanding | Weighted Average Exercise Price | ||||||
| Pre-funded warrants issued in July 2026 | $ | |||||||
| Pre-funded warrants issued in August 2026 | $ | |||||||
| Pre-funded warrants issued in September 2026 | $ | |||||||
| Outstanding at September 30, 2026 | $ | |||||||
A summary of pre-funded warrant activity during the nine months ended September 30, 2026 is as follows:
| Number of Pre-Funded Warrants | Weighted Average Exercise Price | |||||||
| Outstanding at January 1, 2026 | $ | |||||||
| Pre-funded warrants granted | $ | |||||||
| Pre-funded warrants exercised | ( | ) | $ | ( | ) | |||
| Outstanding at September 30, 2026 | $ | |||||||
Pre-funded Warrants Issued in February 2026
In February 2026, the Company entered into securities purchase agreements (the “Purchase Agreements”) with certain institutional investors (the “Purchasers”) for the issuance and sale in a private placement (the “Private Placement”) of (i)
The Pre-funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $
All of the pre-funded warrants issued in February 2026 were cash exercised in the nine months ended September 30, 2026.
Pre-funded Warrants Issued in July 2026
On July 22, 2026, the Company entered into an Equity Purchase Agreement (the “Purchase Agreement”) with Hudson Global Ventures, LLC (“Hudson”). Pursuant to the Purchase Agreement, upon the terms and subject to the conditions set forth therein, the Company may, from time to time during the Commitment Period, in its sole discretion, require Hudson to purchase shares of the Company’s common stock, having an aggregate purchase price of up to $
33
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 13 – EQUITY (continued)
Pre-Funded Warrants (continued)
Pre-funded Warrants Issued in August 2026
On August 14, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
Pre-funded Warrants Issued in September 2026
On September 8, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
On each of September 10, 2026 and September 14, 2026, the Company entered into certain waivers (the “September 2026 Waiver”) with each of Dune Equity Holdings, LLC (“Dune”) and FirstFire Opportunities Fund, LLC (“Firstfire”) of provisions under outstanding notes held by them to allow for the Company to issue the September 2026 OID Notes. In consideration of these September 2026 Waivers, the Company agreed to issue each of Dune and FirstFire pre-funded warrants (collectively, the “Waiver Pre-Funded Warrants”) to purchase
On September 30, 2026, the Company issued promissory notes to certain accredited investors in the aggregate principal amount of $
NOTE 14 – STATUTORY RESERVE AND RESTRICTED NET ASSETS
The Company’s PRC subsidiary, Avalon Shanghai, is restricted in its ability to transfer a portion of its net asset to the Company. The payment of dividends by entities organized in China is subject to limitations, procedures and formalities. Regulations in the PRC currently permit payment of dividends only out of accumulated profits as determined in accordance with accounting standards and regulations in China.
The Company is required to make appropriations to certain reserve funds, comprising the statutory surplus reserve and the discretionary surplus reserve, based on after-tax net income determined in accordance with generally accepted accounting principles of the PRC (“PRC GAAP”). Appropriations to the statutory surplus reserve are required to be at least
34
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 14 – STATUTORY RESERVE AND RESTRICTED NET ASSETS (continued)
Relevant PRC laws and regulations restrict the Company’s PRC subsidiary, Avalon Shanghai, from transferring a portion of its net assets, equivalent to its statutory reserve and its share capital, to the Company’s shareholders in the form of loans, advances or cash dividends. Only PRC entity’s accumulated profit may be distributed as dividend to the Company’s shareholders without the consent of a third party. As of both September 30, 2026 and December 31, 2025, total restricted net assets amounted to $
NOTE 15 – CONDENSED FINANCIAL INFORMATION OF THE PARENT COMPANY
Pursuant to the requirements of Rule 12-04(a), 5-04(c) and 4-08(e)(3) of Regulation S-X, the condensed financial information of the parent company shall be filed when the restricted net assets of consolidated subsidiary exceed
The Company performed a test on the restricted net assets of consolidated subsidiary in accordance with such requirement and concluded that it was not applicable to the Company as the restricted net assets of the Company’s PRC subsidiary did not exceed
NOTE 16 – CONCENTRATIONS
Suppliers
No supplier accounted for 10% or more of the Company’s purchase during the three and nine months ended September 30, 2026 and 2025.
NOTE 17 – COMMITMENTS AND CONTINGENCIES
Litigation
From time to time, the Company is subject to ordinary routine litigation incidental to its normal business operations. The Company is not currently a party to, and its property is not subject to, any material legal proceedings, except as set forth below.
On October 28, 2019, Research Institute at Nationwide Children’s Hospital (“Research Institute”) filed a Complaint in the United States District Court for the Southern District of Ohio Eastern Division against Dr. Zhou, Li Chen, the Company and Genexosome with various claims against the Company and Genexosome including misappropriation of trade secrets in violation of the Defend Trade Secrets Act of 2016 and violation of Ohio Uniform Trade Secrets Act. The Company, Genexosome and the Research Institute entered into a Settlement Agreement dated June 7, 2022 (the “Settlement Date”) whereby the Company agreed to pay the Research Institute $
Operating Leases Commitment
The Company is a party to leases for office space. These lease agreements expire through February 2029. Rent expense under all operating leases amounted to approximately $
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Cash paid for amounts included in the measurement of lease liabilities: | ||||||||
| Operating cash flows paid for operating lease | $ | $ | ||||||
| Right-of-use assets obtained in exchange for lease obligation: | ||||||||
| Operating lease | $ | $ | ||||||
35
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 17 – COMMITMENTS AND CONTINGENCIES (continued)
Operating Leases Commitment (continued)
The following table summarizes the lease term and discount rate for the Company’s operating leases as of September 30, 2026:
| Operating Lease | ||||
| Weighted average remaining lease term (in years) | ||||
| Weighted average discount rate | % | |||
The following table summarizes the maturity of lease liabilities under operating leases as of September 30, 2026:
| For the Twelve-month Period Ending September 30: | Operating Lease | |||
| 2027 | $ | |||
| 2028 | ||||
| 2029 | ||||
| 2030 and thereafter | ||||
| Total lease payments | ||||
| Amount of lease payments representing interest | ( | ) | ||
| Total present value of operating lease liabilities | $ | |||
| Current portion | $ | |||
| Long-term portion | ||||
| Total | $ | |||
NOTE 18 – SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the financial statements were issued. Based upon this review, other than as described below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.
Sales under Equity Purchase Agreement
In October 2026, the Company sold
Advance from Related Party
On October 13, 2026, the Company’s CSO advanced the Company $
36
CHANGE AGENTS CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 18 – SUBSEQUENT EVENTS (continued)
Waivers and Pre-Funded Warrants
On October 14, 2026, the Company entered into certain waivers (the “October 2026 Waivers”) with each of Dune Equity Holdings, LLC (“Dune”) and FirstFire Global Opportunities Fund, LLC (“Firstfire”) to waive their prepayment provisions with respect to a recent note issuance and recent sale of shares under an equity purchase agreement. In consideration of the October 2026 Waivers, the Company issued pre-funded warrants to each of Dune and FirstFire (collectively, the “Waiver Pre-Funded Warrants”) to purchase
Unsecured Promissory Notes
On October 16, 2026, the Company executed unsecured promissory notes in the amounts of $
On November 4, 2026, the Company issued a promissory note to in the amount of $
Amendment to Stock Incentive Plan
On October 30, 2026, the Company adopted Amendment No. 1 to the Avalon GloboCare Corp. Stock Incentive Plan (the “Plan Amendment’) to increase the number of shares of common stock reserved for issuance thereunder to
Share Issuance to Consultants
On November 4, 2026, the Company agreed to issue
Appointment of Principal Executive Officer
On November 4, 2026, Luisa Ingargiola, Chief Strategy Officer of the Company, was appointed as principal executive officer of the Company, to serve in such role until such time as the Company appoints a new Chief Executive Officer.
Exercise of Pre-funded Warrants
During the period from October 1, 2026 through November 9, 2026, the Company issued a total of
37
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This Quarterly Report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “will,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future. Accordingly, factors that may affect our results include, but are not limited to:
| ● | our ability to commercialize our product candidates and the growth of the markets for those product candidates; |
| ● | our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors; and |
| ● | a decline in economic conditions, including the impact of an inflationary environment and tariffs. |
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the filing date of this Quarterly Report on Form 10-Q or the date of the document incorporated by reference into this Quarterly Report on Form 10-Q. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith, and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.
The following discussion and analysis of our financial condition and results of operations for the three and nine months ended September 30, 2026 and 2025 should be read in conjunction with our condensed consolidated financial statements and related notes to those condensed consolidated financial statements that are included elsewhere in this Quarterly Report on Form 10-Q.
Overview
We are a technology-focused company with a strategic focus on developing innovative Agentic AI software and consumer health products that target consumers and small businesses. We recently announced our intent to expand into drone interception and surveillance AI enhanced technology solutions through the establishment of Autonomous Air Defense Systems LLC. While we continue to develop the Catch-Up and Beacon agentic software products, we continue to evaluate possible AI acquisitions that we believe could generate near-term revenue to supplement our current operations while our two products continue through their development and commercial launch phases. Throughout our operating history, we have maintained our corporate identity, management team and original mission while strategically evolving our business in response to market conditions and commercial opportunities, with each such evolution being the product of deliberate decisions. We are actively seeking complementary bolt-on AI acquisitions that could generate near-term revenue to supplement our current operations as both segments continue to develop. We believe our diverse and evolving portfolio of commercial activities reflects our ongoing commitment to identifying and building value-oriented technology businesses for the benefit of its stockholders.
We had the following areas of focus in the three and nine months ended September 30, 2026 and 2025:
We currently operate through two business segments: (i) an artificial intelligence software segment, through which we develop and commercialize an AI-driven, short-form agentic video generation platform and an agentic Generative Engine Optimization (GEO) search product operated by Avalon Quantum AI, LLC, our wholly owned subsidiary formed in connection with our acquisition of RPM Interactive, Inc. in December 2025; and (ii) a consumer health technology segment, through which we distributes the Keto Air breathalyzer device - a non-invasive consumer breathalyzer that measures ketosis levels and is sold in North America, bearing an FDA registration number. Each segment is described more fully below.
38
Artificial Intelligence Software Segment - Avalon Quantum AI, LLC / RPM Interactive
Our artificial intelligence software segment is operated through Avalon Quantum AI, LLC, a wholly owned subsidiary of our company organized in the State of Nevada and formed in connection with our acquisition of RPM Interactive, Inc. (“RPM”) in December 2025. RPM merged with and into Avalon Quantum AI, LLC pursuant to the merger, and Avalon Quantum AI, LLC continues to operate as our wholly owned subsidiary. Avalon Quantum AI LLC is advancing next-generation Agentic AI software products that we believe are designed to deliver material revenue increases for small businesses and content creators.
Catch-Up Phase 2 Development
Phase 2 of the Catch-Up platform is currently in development and is expected to launch in Q4 of 2026. As announced on March 31, 2026, the Company hired Caylent, Inc. a cloud-native services company and an Amazon Web Services (AWS) Premier Tier Consulting Partner, to support the development of this Phase 2 AWS-based initiative. This Phase 2 development is expected to transition the platform from a manually configured AI video production system into a fully autonomous, agentic AI-driven video platform. Phase 2 is expected to expand the platform’s user base beyond podcasters to a substantially broader range of content creators and marketers, including social media influencers and individuals or businesses engaged in product marketing and e-commerce.
The Beacon Agentic Generative Engine Optimization (GEO) Search Product
The Beacon Agentic GEO search product is designed to help small, local service businesses get recommended by AI systems like ChatGPT, Gemini, Claude, Perplexity and Grok. The agentic software product is designed to autonomously; a) diagnose a small businesses AI visibility and SEO effectiveness in about 60 seconds, b) provide a visibility score, and c) generate implementation-ready fixes upon approval. The Beacon app launched in Q3 of 2026 and is commercially available. It is being actively marketed to small businesses through a monthly subscription fee.
Consumer Health Technology Segment - Keto-Air Breathalyzer
Our consumer health technology segment is centered on the Keto Air breathalyzer device, a non-invasive consumer health product that allows users to determine whether they are in a state of nutritional ketosis, and at what level, by exhaling into a compact, pen-like breathalyzer. Ketosis is a metabolic state in which the body burns fat for fuel rather than carbohydrates, and is widely associated with low-carbohydrate and ketogenic dietary regimens. The Keto Air device represents a meaningful improvement over prior methods of measuring ketosis, such as urine test strips or earlier-generation breathalyzers that required cartridge replacements, offering users a convenient, reusable, and non-invasive testing experience. We sell our product through a distribution agreement into North America.
Cessation of Laboratory Services
During the first quarter of 2025, to preserve cash, the Company entered into discussions with Lab Services MSO for the potential redemption of our investment and on February 26, 2025, we and Lab Services MSO entered into a Redemption and Abandonment Agreement, whereby Lab Services MSO redeemed the 40% equity interest in Lab Services MSO held by us. Accordingly, beginning in February 2025, we no longer offer laboratory services.
Other Areas
In order to preserve cash and focus on product commercialization, we have suspended all research and development efforts related to cellular therapy. We are redirecting our funding efforts to our core business strategies outlined above.
39
Recent Developments
Sales under Equity Purchase Agreement
In October 2026, the Company sold 112,500 shares of its common stock to Hudson Global Ventures, LLC under its Equity Purchase Agreement with them for which the Company received $225,000 in gross proceeds.
Advance from Related Party
On October 13, 2026, the Company’s CSO advanced the Company $7,500 so that the Company would timely make a loan payment under its Business Loan and Security Agreement with Agile Funding. The Company repaid this advance in October 2026.
Waivers and Pre-Funded Warrants
On October 14, 2026, the Company entered into certain waivers (the “October 2026 Waivers”) with each of Dune Equity Holdings, LLC (“Dune”) and FirstFire Global Opportunities Fund, LLC (“Firstfire”) to waive their prepayment provisions with respect to a recent note issuance and recent sale of shares under an equity purchase agreement. In consideration of the October 2026 Waivers, the Company issued pre-funded warrants to each of Dune and FirstFire (collectively, the “Waiver Pre-Funded Warrants”) to purchase 62,000 and 37,500 shares of common stock, par value $0.0001 per share (“Common Stock”), respectively (collectively, the “Waiver Pre-Funded Warrant Shares). The Waiver Pre-Funded Warrants are immediately exercisable and may be exercised at a nominal exercise price of $0.0001 per share of Common Stock at any time until all of the Waiver Pre-Funded Warrants are exercised in full; provided, however, that until the Company has obtained stockholder approval for issuance of the Waiver Pre-Funded Warrant Shares, the Company shall not issue a number of Waiver Pre-Funded Warrant Shares, which when aggregated with all other securities that are required to be aggregated for purposes of Nasdaq Listing Rule 5635(d), would exceed 19.99% of the shares of Common Stock outstanding as of the date of definitive agreement with respect to the first of such aggregated transactions A holder may not exercise any portion of the Waiver Pre-Funded Warrants to the extent the Purchaser would own more than 4.99% of the outstanding Common Stock immediately after exercise. A holder may increase or decrease this percentage with respect to Waiver Pre-Funded Warrants to a percentage not in excess of 9.99%, except that any such increase shall require at least 61 days’ prior notice to the Company. The Waiver Pre-Funded Warrants also provide that if the Company fails to procure stockholder approval for issuance of the Waiver Pre-Funded Warrant Shares on or before the date which is 90-days after issuance of the Waiver Pre-Funded Warrants, then the holders of such warrants will have the right to require the Company to pay a buyout fee redeem the warrants in the amount of $150,000 for Dune and $75,000 for FirstFire unless this Pre-Funded Warrants are exercisable in full on the Stockholder Approval Deadline Date in accordance with Nasdaq Listing Rule 5635(d), in which case no buyout amount shall be due and payable. The October 2026 Waivers also granted piggyback registration rights.
Unsecured Promissory Notes
On October 16, 2026, the Company executed unsecured promissory notes in the amounts of $150,000 and $100,000 with amounts due at maturity on December 1, 2026 of $183,335 and $116,665, respectively.
On November 4, 2026, the Company issued a promissory note to in the amount of $250,000 with an original issue discount of $75,000. The Company is required to repay this note on January 1, 2027 in the amount of $325,000. The Company may prepay this note on December 1, 2026 for $312,000.
Amendment to Stock Incentive Plan
On October 30, 2026, the Company adopted Amendment No. 1 to the Avalon GloboCare Corp. Stock Incentive Plan (the “Plan Amendment’) to increase the number of shares of common stock reserved for issuance thereunder to 500,000 shares from 100,000 shares.
Share Issuance to Consultants
On November 4, 2026, the Company agreed to issue 150,000 shares of its common stock to certain consultants under consulting agreements in consideration of services rendered.
Appointment of Principal Executive Officer
On November 4, 2026, Luisa Ingargiola, Chief Strategy Officer of the Company, was appointed as principal executive officer of the Company, to serve in such role until such time as the Company appoints a new Chief Executive Officer.
Exercise of Pre-funded Warrants
During the period from October 1, 2026 through November 9, 2026 the Company issued a total of 159,669 shares of its common stock upon exercise of pre-funded warrants.
40
Going Concern
Our condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business.
As reflected in the accompanying condensed consolidated financial statements, we had working capital deficit of approximately $5,972,000 at September 30, 2026 and had incurred recurring net losses from continuing operations and generated negative cash flow from operating activities of continuing operations of approximately $10,184,000 and $4,720,000 for the nine months ended September 30, 2026, respectively.
We have a limited operating history and our continued growth is dependent upon generating revenue from advanced Agentic AI systems, including automated video generation and small business marketing automation, the continuation of generating revenue for selling of Keto Air, and obtaining additional financing to fund future obligations and pay liabilities arising from ordinary course business operations. In addition, the current cash balance cannot be projected to cover our operating expenses for the next twelve months from the release date of this Quarterly Report on Form 10-Q. These matters raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital, implement our business plan, and generate sufficient revenues. There are no assurances that we will be successful in our efforts to generate sufficient revenues, maintain sufficient cash balance or report profitable operations or to continue as a going concern. We plan on raising capital through the sale of equity to implement our business plan. However, there is no assurance these plans will be realized and that any additional financings will be available to us on satisfactory terms and conditions, or at all.
The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should we be unable to continue as a going concern.
Critical Accounting Policies
Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in these estimates and assumptions may have a material impact on the condensed consolidated financial statements and accompanying notes. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Significant estimates during the three and nine months ended September 30, 2026 and 2025 include the useful life of intangible assets, the assumptions used in assessing impairment of long-term assets, the allowance for credit loss, the valuation of deferred tax assets and the associated valuation allowances, the valuation of stock-based compensation, the valuation of Series D convertible preferred stock (“Series D Preferred Stock”), and the determination of the fair value of the warrants.
Income Taxes
We are governed by the income tax laws of China and the United States. Income taxes are accounted for pursuant to ASC 740 “Accounting for Income Taxes,” which is an asset and liability approach that requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our financial statements or tax returns. The charge for taxes is based on the results for the period as adjusted for items, which are non-assessable or disallowed. It is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date.
Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in the computation of assessable tax profit. In principle, deferred tax liabilities are recognized for all taxable temporary differences, and deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which deductible temporary differences can be utilized.
Deferred tax is calculated using tax rates that are expected to apply to the period when the asset is realized or the liability is settled. Deferred tax is charged or credited in the income statement, except when it is related to items credited or charged directly to equity, in which case the deferred tax is changed to equity. Deferred tax assets and liabilities are offset when they related to income taxes levied by the same taxation authority and we intend to settle its current tax assets and liabilities on a net basis.
41
Recent Accounting Standards
For details of applicable new accounting standards, please, refer to Recent Accounting Standards in Note 3 of our condensed consolidated financial statements accompanying this Quarterly Report on Form 10-Q.
RESULTS OF OPERATIONS
Comparison of Results of Operations for the Three and Nine Months Ended September 30, 2026 and 2025
Income from Equity Method Investment – Lab Services MSO
As a result of the sale of our ownership of 40% of Lab Services MSO on February 26, 2025, we had no income from our investment in Lab Services MSO after February 2025.
For the nine months ended September 30, 2025, we had income from our investment in Lab Services MSO of $392,677, which consists of our share of Lab Services MSO’s net income of $503,833 and amortization of identifiable intangible assets acquired from Lab Services MSO acquisition of $111,156.
Other Operating Expenses
For the three and nine months ended September 30, 2026 and 2025, other operating expenses consisted of the following:
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Advertising and marketing expenses | $ | 37,369 | $ | 249,021 | $ | 352,486 | $ | 642,723 | ||||||||
| Professional fees | 1,573,736 | 1,217,025 | 3,951,264 | 4,277,851 | ||||||||||||
| Compensation and related benefits | 235,786 | 201,375 | 893,927 | 803,026 | ||||||||||||
| Credit loss expense | - | (1,650,000 | ) | - | - | |||||||||||
| Miscellaneous taxes | 40,600 | 43,600 | 129,694 | 128,713 | ||||||||||||
| Directors’ and officers’ liability insurance premium | 35,877 | 34,227 | 104,085 | 105,712 | ||||||||||||
| Travel and entertainment | 26,237 | 21,109 | 87,933 | 104,091 | ||||||||||||
| Amortization | 563,000 | - | 1,689,000 | - | ||||||||||||
| Other general and administrative | 51,792 | 15,103 | 129,013 | 155,960 | ||||||||||||
| $ | 2,564,397 | $ | 131,460 | $ | 7,337,402 | $ | 6,218,076 | |||||||||
| ● | For the three months ended September 30, 2026, advertising and marketing expenses decreased by $211,652, or 85.0%, as compared to the three months ended September 30, 2025. For the nine months ended September 30, 2026, advertising and marketing expenses decreased by $290,237, or 45.2%, as compared to the nine months ended September 30, 2025. The decrease was primarily due to decreased advertising activities in the three and nine months ended September 30, 2026 as compared to the corresponding periods of 2025. We expect that our advertising and marketing expenses will likely remain at its current quarterly level with minimal increase in the near future. |
| ● | Professional fees primarily consisted of accounting fees, audit fees, legal service fees, consulting fees, investor relations service charges, advisory service fees, fairness opinion charge, valuation service fees and other fees. For the three months ended September 30, 2026, professional fees increased by $356,711, or 29.3%, as compared to the three months ended September 30, 2025, which was primarily attributable to an increase in legal service fees of approximately $530,000 resulting from the increase in legal service providers, and an increase in other miscellaneous items of approximately $157,000, offset by a decrease in consulting fee of approximately $330,000, mainly due to the decrease in use of consulting service providers related to capital markets advisory and services related to our potential merger with YOOV. For the nine months ended September 30, 2026, professional fees decreased by $326,587, or 7.6%, as compared to the nine months ended September 30, 2025, which was primarily attributable to a decrease in consulting fee of approximately $590,000, mainly due to the decrease in use of consulting service providers related to capital markets advisory and services related to our potential merger with YOOV, a decrease in accounting fee of approximately $308,000, mainly due to the decreased accounting services related to our potential merger with YOOV, and a decrease in fairness opinion charge of approximately $129,000, mainly due to the decreased fairness opinion services related to our potential merger with YOOV, offset by an increase in investor relations service charges of approximately $268,000, mainly due to the increase in investor relations service providers, an increase in legal service fees of approximately $301,000 resulting from the increase in legal service providers, and an increase in other miscellaneous items of approximately $131,000. We expect that our professional fees will decrease in the near future. |
42
| ● | For the three months ended September 30, 2026, compensation and related benefits increased by $34,411, or 17.1%, as compared to the three months ended September 30, 2025, which was primarily attributable to an increase in stock-based compensation which reflected the value of options granted and vested to our management in the third quarter of 2026 as compared to the corresponding period of 2025. For the nine months ended September 30, 2026, compensation and related benefits increased by $90,901, or 11.3%, as compared to the nine months ended September 30, 2025, which was primarily attributable to an increase in stock-based compensation of approximately $229,000 which reflected the value of options granted and vested to our management in the nine months ended September 30, 2026, offset by a decrease in cash compensation for our directors and officers of approximately $138,000. We expect that our compensation and related benefits will likely decrease in the near future. |
| ● | For the three months ended September 30, 2025, we recorded credit loss recovery of $1,650,000. Based on our periodic review of receivable from sale of equity method investment balance, we adjusted the allowance for credit loss after considering management’s evaluation of the collectability of the receivable balance, including the analysis of subsequent collection, age of the balance, Lab Services MSO’s collection history, and recent economic events. After unsuccessful collection efforts during the second quarter of 2025, management had decided to write off the receivable. On or about July 22, 2025, we filed a lawsuit against Lab Services MSO. We and Lab Services MSO entered into a Confidential Settlement Agreement and Mutual Release dated August 26, 2025 whereby Lab Services MSO agreed to pay us in the aggregate of $1,722,000, of which $600,000 was paid on August 29, 2025 and $1,122,000 to be paid on or before the first business day of each month, beginning September 2025 and ending August 2026, in monthly installments of $93,500. The parties provided a mutual release, as well. The suit was dismissed in August 2025. As a result, for the three months ended September 30, 2025, we recorded a credit loss recovery of $1,650,000 to reinstate the receivable which was written-off in the second quarter of 2025. For the nine months ended September 30, 2025, our credit loss recovery, net, was $0. For the three and nine months ended September 30, 2026, we did not record any credit loss recovery. |
| ● | For the three months ended September 30, 2026, miscellaneous taxes decreased by $3,000, or 6.9%, as compared to the three months ended September 30, 2025. For the nine months ended September 30, 2026, miscellaneous taxes increased by $981, or 0.8%, as compared to the nine months ended September 30, 2025. We expect that our miscellaneous taxes will remain relatively steady, with minimal increase, in the near future. |
| ● | For the three months ended September 30, 2026, directors’ and officers’ liability insurance premium increased by $1,650, or 4.8%, as compared to the three months ended September 30, 2025. For the nine months ended September 30, 2026, directors’ and officers’ liability insurance premium decreased by $1,627, or 1.5%, as compared to the nine months ended September 30, 2025. |
| ● | For the three months ended September 30, 2026, travel and entertainment expense increased by $5,128, or 24.3%, as compared to the three months ended September 30, 2025. For the nine months ended September 30, 2026, travel and entertainment expense decreased by $16,158, or 15.5%, as compared to the nine months ended September 30, 2025, which was primarily attributable to the decreased business travel activities in the nine months ended September 30, 2026 as compared to the comparable period of 2025. We expect that our travel and entertainment expense will remain relatively steady, with minimal increase, in the near future. |
| ● | For the three months ended September 30, 2026, amortization expense increased by $563,000, or 100.0%, as compared to the three months ended September 30, 2025. For the nine months ended September 30, 2026, amortization expense increased by $1,689,000, or 100.0%, as compared to the nine months ended September 30, 2025. The increase was attributable to increased amortization of identifiable intangible assets acquired, representing developed technology and trade name. There was no comparable amortization prior to the date of acquisition, December 12, 2025. |
| ● | Other general and administrative expenses mainly consisted of NASDAQ listing fee, office supplies, and other miscellaneous items. For the three months ended September 30, 2026, other general and administrative expenses increased by $36,689, or 242.9%, as compared to the three months ended September 30, 2025, which was primarily attributable to the increase in computer expense in the third quarter of 2026 as compared to the corresponding period of 2025. For the nine months ended September 30, 2026, other general and administrative expenses decreased by $26,947, or 17.3%, as compared to the nine months ended September 30, 2025, which was due to our efforts at stricter controls on corporate expenditure. |
Loss from Operations
As a result of the foregoing, for the three months ended September 30, 2026, loss from operations amounted to $2,564,397, as compared to $131,460 for the three months ended September 30, 2025, representing an increase of $2,432,937, or 1,850.7%. As a result of the foregoing, for the nine months ended September 30, 2026, loss from operations amounted to $7,337,402, as compared to $5,825,399 for the nine months ended September 30, 2025, representing an increase of $1,512,003, or 26.0%.
43
Other Income (Expense)
Other expense mainly includes interest expense, change in fair value of derivative liability, loss on extinguishment of debt, and other miscellaneous income (expense).
Other expense totaled $1,064,014 for the three months ended September 30, 2026, as compared to other income of $8,829 for the three months ended September 30, 2025, representing a decrease of $1,072,843, or 12,151.4%, which was primarily attributable to a decrease in gain from change in fair value of derivative liability of approximately $34,000, a decrease in other income of approximately $160,000, and an increase in interest expense of approximately $879,000, mainly driven by the increase in amortization of debt discount and debt issuance costs of approximately $304,000 and the increase in interest expense of approximately $575,000 from debts.
Other expense totaled $2,846,501 for the nine months ended September 30, 2026, as compared to $9,848,523 for the nine months ended September 30, 2025, representing a decrease of $7,002,022, or 71.1%, which was primarily attributable to a decrease in loss on extinguishment of debt of approximately $9,077,000, offset by an increase in interest expense of approximately $165,000, mainly driven by the increase in interest expense of approximately $670,000 from debts, offset by the decrease in amortization of debt discount and debt issuance costs of approximately $505,000, a decrease in gain from change in fair value of derivative liability of approximately $1,756,000, and a decrease in other income of approximately $154,000.
Income Taxes
We did not have any income taxes expense for the three and nine months ended September 30, 2026 and 2025 since we incurred losses in these periods.
Net Loss from Continuing Operations
As a result of the factors described above, our net loss from continuing operations was $3,628,411 for the three months ended September 30, 2026, as compared to $122,631 for the three months ended September 30, 2025, representing an increase of $3,505,780, or 2,858.8%.
As a result of the factors described above, our net loss from continuing operations was $10,183,903 for the nine months ended September 30, 2026, as compared to $15,673,922 for the nine months ended September 30, 2025, representing a decrease of $5,490,019, or 35.0%.
Net Loss from Discontinued Operations
Our net loss from discontinued operations was $0 for the three months ended September 30, 2026, as compared to $131,637 for the three months ended September 30, 2025, representing a decrease of $131,637, or 100.0%.
Our net loss from discontinued operations was $103,015 for the nine months ended September 30, 2026, as compared to $521,055 for the nine months ended September 30, 2025, representing a decrease of $418,040, or 80.2%.
Net Loss
As a result of the factors described above, our net loss was $3,628,411 for the three months ended September 30, 2026, as compared to $254,268 for the three months ended September 30, 2025, representing an increase of $3,374,143, or 1,327.0%.
As a result of the factors described above, our net loss was $10,286,918 for the nine months ended September 30, 2026, as compared to $16,194,977 for the nine months ended September 30, 2025, representing a decrease of $5,908,059, or 36.5%.
Net Loss Attributable to Change Agents Corporation Common Shareholders
The net loss attributable to our common shareholders was $3,628,411, or $3.53 per share (basic and diluted), for the three months ended September 30, 2026, as compared to $254,268, or $1.25 per share (basic and diluted), for the three months ended September 30, 2025, representing an increase of $3,374,143, or 1,327.0%.
The net loss attributable to our common shareholders was $10,286,918, or $16.64 per share (basic and diluted), for the nine months ended September 30, 2026, as compared to $16,032,504 (after taking into effect $162,473 in deemed contribution), or $122.03 per share (basic and diluted), for the nine months ended September 30, 2025, representing a decrease of $5,745,586, or 35.8%.
44
Foreign Currency Translation Adjustment
Our reporting currency is the U.S. dollar. The functional currency of our U.S. entities is the U.S. dollar and the functional currency of Avalon Shanghai is the Chinese Renminbi (“RMB”). The financial statements of our subsidiary whose functional currency is the RMB are translated to U.S. dollars using period end rate of exchange for assets and liabilities, average rate of exchange for revenues, costs, and expenses and cash flows, and at historical exchange rate for equity. Net gains and losses resulting from foreign exchange transactions are included in the results of operations. As a result of foreign currency translations, which are a non-cash adjustment, we reported a foreign currency translation loss of $294 and a foreign currency translation gain of $271 for the three months ended September 30, 2026 and 2025, respectively. As a result of foreign currency translations, which are a non-cash adjustment, we reported a foreign currency translation loss of $921 and a foreign currency translation gain of $654 for the nine months ended September 30, 2026 and 2025, respectively. This non-cash loss/gain had the effect of increasing/decreasing our reported comprehensive loss in each respective period.
Comprehensive Loss
As a result of our foreign currency translation adjustment, we had comprehensive loss of $3,628,705 and $253,997 for the three months ended September 30, 2026 and 2025, respectively.
As a result of our foreign currency translation adjustment, we had comprehensive loss of $10,287,839 and $16,194,323 for the nine months ended September 30, 2026 and 2025, respectively.
Liquidity and Capital Resources
We have a limited operating history and our continued growth is dependent upon the continuation of generating revenue for selling of Keto Air, generating revenue from advanced Agentic AI systems, including automated video generation and small business marketing automation, as well as obtaining additional financing to fund future obligations and pay liabilities arising from ordinary course business operations. In addition, the current cash balance cannot be projected to cover our operating expenses for the next twelve months from the release date of this report. These matters raise substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern is dependent on our ability to raise additional capital, implement our business plan, and generate sufficient revenues. There are no assurances that we will be successful in our efforts to generate sufficient revenues, maintain sufficient cash balance or report profitable operations or to continue as a going concern. We plan to raise capital in the future through the sale of equity or debt to implement our business plan. However, there is no assurance these plans will be realized and that any additional financings will be available to us on satisfactory terms and conditions, if at all.
Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations as they come due and otherwise operate on an ongoing basis. At September 30, 2026 and December 31, 2025, we had a cash balance of approximately $305,000 and $109,000, respectively. These funds are kept in financial institutions located as follows:
| Country: | September 30, 2026 | December 31, 2025 | ||||||||||||||
| United States | $ | 304,738 | 99.98 | % | $ | 108,599 | 99.5 | % | ||||||||
| China | 76 | 0.02 | % | 492 | 0.5 | % | ||||||||||
| Total cash | $ | 304,814 | 100.0 | % | $ | 109,091 | 100.0 | % | ||||||||
The following table sets forth a summary of changes in our working capital deficit from December 31, 2025 to September 30, 2026:
| September 30, | December 31, | Changes in | ||||||||||||||
| 2026 | 2025 | Amount | Percentage | |||||||||||||
| Working capital deficit: | ||||||||||||||||
| Total current assets | $ | 610,687 | $ | 1,495,877 | $ | (885,190 | ) | (59.2 | )% | |||||||
| Total current liabilities | 6,583,035 | 14,147,114 | (7,564,079 | ) | (53.5 | )% | ||||||||||
| Working capital deficit | $ | (5,972,348 | ) | $ | (12,651,237 | ) | $ | 6,678,889 | (52.8 | )% | ||||||
45
Our working capital deficit decreased by $6,678,889 to $5,972,348 at September 30, 2026 from $12,651,237 at December 31, 2025. The decrease in working capital deficit was primarily attributable to an increase in cash of approximately $196,000, a decrease in accrued liabilities and other payables of approximately $133,000 driven by the payments made to our vendors in the nine months ended September 30, 2026, a decrease in advance from pending sale of subsidiary – related party of approximately $3,158,000 resulting from the sale of our subsidiary of Avalon RT 9 to Mr. Lu in February 2026 as described in elsewhere in this report, a decrease in bridge loan payable, net, of approximately $197,000 due to the repayments made to lender in the nine months ended September 30, 2026, a decrease in convertible note payable, net, of approximately $737,000 mainly due to the conversion of our June 2024 Convertible Note in the principal amount of approximately $546,000 into our common stock in the nine months ended September 30, 2026 and the repayments of principal of $200,000 made to two individual investors in the nine months ended September 30, 2026, and a decrease in current liabilities of discontinued operations of approximately $6,061,000 driven by the sale of our subsidiary of Avalon RT 9 to Mr. Lu in February 2026 as described in elsewhere in this report, offset by a decrease in receivable from sale of equity method investment of $748,000 due to the payments received in the nine months ended September 30, 2026, a decrease in current assets of discontinued operations of approximately $357,000 driven by the sale of our subsidiary of Avalon RT 9 to Mr. Lu in February 2026 as described in elsewhere in this report, an increase in accrued professional fees of approximately $556,000 driven by the increase in professional service providers in the nine months ended September 30, 2026, an increase in note payable, net, of approximately $1,759,000 resulting from our loan financing in the nine months ended September 30, 2026, and an increase in series F convertible redeemable preferred stock, net, of approximately $371,000 driven by our series F preferred stock financing in the nine months ended September 30, 2026.
Because the exchange rate conversion is different for the condensed consolidated balance sheets and the condensed consolidated statements of cash flows, the changes in assets and liabilities reflected on the condensed consolidated statements of cash flows are not necessarily identical with the comparable changes reflected on the condensed consolidated balance sheets.
Cash Flows for the Nine Months Ended September 30, 2026 Compared to the Nine Months Ended September 30, 2025
The following table summarizes the key components of our cash flows for the nine months ended September 30, 2026 and 2025:
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| Net cash used in operating activities from continuing operations | $ | (4,719,942 | ) | $ | (4,075,479 | ) | ||
| Net cash provided by investing activities from continuing operations | 499,707 | 788,500 | ||||||
| Net cash provided by financing activities from continuing operations | 4,605,978 | 1,112,871 | ||||||
| Net cash flows used in discontinued operations | (231,956 | ) | (283,865 | ) | ||||
| Effect of exchange rate on cash – continuing operations | 41,936 | 673 | ||||||
| Net increase (decrease) in cash | $ | 195,723 | $ | (2,457,300 | ) | |||
Net cash flow used in operating activities from continuing operations for the nine months ended September 30, 2026 was $4,719,942, which primarily reflected our consolidated net loss from continuing operations of approximately $10,184,000, offset by the changes in operating assets and liabilities, primarily consisting of an increase in accrued liabilities and other payables of approximately $391,000, and the non-cash item adjustments, primarily consisting of depreciation and amortization of intangible assets of approximately $1,691,000 mainly due to the amortization of identifiable intangible assets acquired, representing developed technology and trade name, in the nine months ended September 30, 2026 as described in elsewhere in this report, stock-based compensation and service expense of approximately $1,180,000, amortization of debt issuance costs and debt discount of approximately $568,000, non-cash interest expense of approximately $217,000, and change in fair market value of derivative liability of approximately $1,284,000.
Net cash flow used in operating activities from continuing operations for the nine months ended September 30, 2025 was $4,075,479, which primarily reflected our consolidated net loss from continuing operations of approximately $15,674,000, and the non-cash item adjustments, consisting of income from equity method investment of approximately $393,000, and change in fair market value of derivative liability of approximately $472,000, and the changes in operating assets and liabilities, primarily consisting of an increase in prepaid expense and other assets of approximately $193,000 mainly due to the increase in prepaid professional fees which were paid by cash of approximately $175,000, offset by an increase in accrued liabilities and other payables of approximately $1,065,000 which was mainly driven by the increase in professional services related to our potential merger with YOOV in the nine months ended September 30, 2025, and the non-cash item adjustments, primarily consisting of stock-based compensation and service expense of approximately $1,423,000, amortization of debt issuance costs and debt discount of approximately $1,073,000, and loss on extinguishment of debt of approximately $9,077,000 resulted from the reduction in the conversion price of our June 2024 Convertible Note.
We expect our cash used in operating activities to increase in the next 12 months due to the following:
| ● | the development and commercialization of new products; and |
| ● | an increase in public relations and/or sales promotions for existing and/or new brands as we expand within existing markets or enter new markets. |
46
Net cash flow provided by investing activities from continuing operations was $499,707 for the nine months ended September 30, 2026, as compared to $788,500 for the nine months ended September 30, 2025. During the nine months ended September 30, 2026, we received proceeds from sale of equity method investment of $748,000, offset by payments made for purchase of property and equipment of approximately $12,000 and for acquisition of software and platform of approximately $236,000. During the nine months ended September 30, 2025, we received proceeds from sale of equity method investment of approximately $789,000.
Net cash flow provided by financing activities from continuing operations was $4,605,978 for the nine months ended September 30, 2026, as compared to $1,112,871 for the nine months ended September 30, 2025. During the nine months ended September 30, 2026, we received net proceeds from issuance of debt of $3,571,000 (net of original issue discount of approximately $415,000 and cash paid for debt issuance costs of $97,000), proceeds from issuance of series F convertible preferred stock of $400,000, and net proceeds from the February 2026 private offering of approximately $2,757,000 (net of cash paid for the February 2026 private offering costs of approximately $493,000), offset by repayments made for bridge loan of $375,000, repayments made for convertible debt of $200,000, repayments made for debt of approximately $1,527,000, and paid for our equity line of credit offering cost of $20,000. During the nine months ended September 30, 2025, we received proceeds from issuance of July 2025 Convertible Note of $200,000, proceeds from stock subscription of $150,000, an advance from pending sale of subsidiary of approximately $50,000, net proceeds from the issuance of convertible preferred stock of $290,000 (net of cash paid for convertible preferred stock issuance costs of $10,000), and proceeds from issuance of common stock and warrants approximately $476,000, offset by payments made for offering costs of approximately $53,000.
The following trends are reasonably likely to result in a material decrease in our liquidity over the near to long term:
| ● | an increase in working capital requirements to finance our current business; |
| ● | the use of capital for acquisitions and the development of business opportunities; and |
| ● | the cost of being a public company. |
In addition, the impact that the imposition of tariffs and changes to global trade policies could have on our results of operations is uncertain.
We estimate that, based on current plans and assumptions, our available cash will be insufficient to satisfy our cash requirements under our present operating expectations through cash flow provided by operations and sales of equity. Other than funds received as described above and cash resources generated from our operations, we presently have no other significant alternative source of working capital. We have used these funds to fund our operating expenses, pay our obligations and grow our company. We will need to raise significant additional capital to fund our operations and to provide working capital for our ongoing operations and obligations. Therefore, our future operation is dependent on our ability to secure additional financing. Financing transactions may include the issuance of equity or debt securities, obtaining credit facilities, or other financing mechanisms. However, there can be no assurance that financing will be available in amounts or on terms acceptable to the Company. Additionally, the trading price of our common stock and a downturn in the U.S. equity and debt markets could make it more difficult to obtain financing through the issuance of equity or debt securities. Even if we are able to raise the funds required, it is possible that we could incur unexpected costs and expenses or experience unexpected cash requirements that would force us to seek alternative financing. Furthermore, if we issue additional equity or debt securities, stockholders may experience additional dilution or the new equity securities may have rights, preferences or privileges senior to those of existing holders of our common stock. The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional financing, we will be required to cease our operations. To date, we have not considered this alternative, nor do we view it as a likely occurrence.
Foreign Currency Exchange Rate Risk
We ceased all operations in China in 2022, with the exception of a small administrative office. We did not during the nine months ended September 30, 2026, and do not expect in the foreseeable future, to generate any additional revenue from PRC operations. Thus, exchange rate fluctuations between the RMB and the U.S. dollar do not, and are not expected to, have a material effect on us. For the three months ended September 30, 2026 and 2025, we had an unrealized foreign currency translation loss of approximately $300 and an unrealized foreign currency translation gain of approximately $300, respectively, because of changes in the exchange rate. For the nine months ended September 30, 2026 and 2025, we had an unrealized foreign currency translation loss of approximately $900 and an unrealized foreign currency translation gain of approximately $700, respectively, because of changes in the exchange rate.
Inflation
The effect of inflation on our revenues and operating results was not significant for the three and nine months ended September 30, 2026 and 2025.
47
Issuer and Guarantor Summarized Financial Information
Change Agents Corporation’s wholly-owned subsidiaries, Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., and Avalon Quantum AI LLC guaranteed the July 2026 Business Loan and the July 2026 Secured Note. The restrictive covenants include customary restrictions on Change Agents Corporation’s ability to incur additional debt; make investments; grant or incur liens on assets; sell assets; engage in mergers, consolidations, liquidations or dissolutions; engage in transactions with affiliates; and make dividend payments. In addition, the July 2026 Business Loan Agreement contains customary representations and warranties, affirmative covenants and events of default. None of Change Agents Corporation’s other subsidiaries are guarantors of July 2026 debt.
The tables below present combined summarized financial information for Avalon Healthcare System Inc., Avalon Laboratory Services, Inc., and Avalon Quantum AI LLC (individually and collectively, jointly and severally, “Guarantors”), and Change Agents Corporation, the issuer (jointly the “Obligor Group”) as standalone companies after elimination of intercompany transactions and balances, and do not include nonguarantor and nonissuer subsidiaries. This summarized financial information has been prepared and presented pursuant to the Securities and Exchange Commission Regulation S-X Rule 13-01, “Financial Disclosures about Guarantors and Issuers of Guaranteed Securities” and is not intended to present the financial position or results of operations of the Obligor Group in accordance with U.S. GAAP.
Summarized Balance Sheet Information for the Obligor Group:
| At | At | |||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Current assets | $ | 593,142 | $ | 1,479,076 | ||||
| Noncurrent assets | $ | 14,103,118 | $ | 21,904,133 | ||||
| Noncurrent assets - due from consolidated entities outside of Obligor Group | $ | 3,687,089 | $ | 3,687,089 | ||||
| Total noncurrent assets | $ | 17,790,207 | $ | 25,591,222 | ||||
| Total current liabilities | $ | 6,542,854 | $ | 14,108,616 | ||||
| Total noncurrent liabilities | $ | 35,002 | $ | 23,515 | ||||
Summarized Statements of Operations Information for the Obligor Group:
| Nine Months Ended | Year Ended | |||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Income from equity method investment - Lab Services MSO | $ | - | $ | 392,677 | ||||
| Other operating expenses | $ | (7,337,168 | ) | $ | (7,898,124 | ) | ||
| Loss from operations | $ | (7,337,168 | ) | $ | (7,505,447 | ) | ||
| Other expense, net | $ | (2,846,514 | ) | $ | (9,927,522 | ) | ||
| Net loss from continuing operations | $ | (10,183,682 | ) | $ | (17,432,969 | ) | ||
48
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.
As a “smaller reporting company”, as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures are designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s (the “SEC”) rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed under the Exchange Act is accumulated and communicated to management, including the principal executive and financial officers, as appropriate to allow timely decisions regarding required disclosure. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.
In connection with the preparation of this Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, our management, including our principal executive officer and principal financial officer, carried out an evaluation, as of September 30, 2026, of the effectiveness of our disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Exchange Act.
Based on this evaluation, management concluded that our disclosure controls and procedures were not effective as of September 30, 2026 due to the material weaknesses related to the lack of segregation of duties resulting from our small size and inability to perform an effective test of the operating effectiveness of the controls, including the oversight of our financial statement close process that was previously reported in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, that have not yet been remediated.
Management’s plan to remediate these material weaknesses is described in detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
49
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, we believe would individually or in the aggregate have a material adverse effect on our business, results of operations, financial condition or cash flows.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, as the same may be updated from time to time, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K may not be the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
As a smaller reporting company, the Company is not required to disclose material changes to the risk factors that were contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as the same may be updated from time to time.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
On September, 22, 2026, we issued 15,000 shares of common stock to a June 2026 noteholder in consideration of a most-favored nations provision under such June 2026 note. No proceeds were received. The issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended.
In October 2026, we sold 112,500 shares of our common stock to Hudson Global Ventures, LLC under our Equity Purchase Agreement with them for which we received $225,000 in gross proceeds. The proceeds were used for repayment of indebtedness, working capital and general corporate purposes. The shares were issued under the exemption from registration provide by Section 4(a)(2) of the Securities Act of 1933, as amended.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
50
ITEM 6. EXHIBITS
The exhibits filed as part of this Quarterly Report on Form 10-Q are listed in the exhibit index included herewith and are incorporated by reference herein.
EXHIBIT INDEX
51
| * | Filed herewith. |
| ** | Furnished herewith. |
52
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CHANGE AGENTS CORPORATION | ||
| By: | /s/ Luisa Ingargiola | |
| Dated: November 16, 2026 | Name: | Luisa Ingargiola |
| Title: | Chief Strategy Officer | |
| (Principal Executive Officer) | ||
| By: | /s/ Sam Knipper | |
| Dated: November 16, 2026 | Name: | Sam Knipper |
| Title: | Chief Financial Officer | |
| (Principal Financial and Accounting Officer) | ||
53